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ABSTRACT OF DISSERTATION 
 
THE EFFECTS OF A WORKSITE WELLNESS PROGRAM ON PRESCRIPTION 
CLAIMS 
The purpose of this study was to determine the effectiveness of the worksite wellness 
weight loss program called Weight Loss Matters (WLM) for employees at the University 
of Kentucky.  The three main objectives were to measure the effect of Weight Loss 
Matters for employees from June 2006 to December 2011 in the following areas (1) 
prescription claims for hypertension, diabetes, and dyslipidemia, (2) weight loss, and (3) 
food diary compliance.  Participants included 591 employees who participated in WLM 
for at least one session from 2006 to 2011 for whom there were data.  This study 
employed a Quasi-experiment, longitudinal design.  Data were collected from WLM 
records and UK health plan records.  Data obtained from WLM included attendance, 
physical activity reported, food diary compliance, participation goal, height, and weight.  
Measures from the health plan database were prescription claims for hypertension, 
diabetes, and cholesterol at twelve months prior to start date, six months post-start date, 
and 12 months post-start date for each participant.  Data analysis included Chi Square, 
Fishers Exact, ANOVA, ANCOVA, linear and logistic regression.  After completing two 
sessions of WLM, a significant number of participants ceased taking hypertension 
medications at six and 12 months post-WLM.  There was significant weight loss for all 
participants after one class.  For continued attendance (multiple sessions,) participants 
continued to have small weight losses.  Analysis showed a significant relationship 
between weight loss and food diary completion, with the more food diaries completed, 
the more weight was lost. Food diary compliance and attendance were significant 
predictors of weight loss.  Information gained from this study will be helpful in designing 
future weight loss programs at the University of Kentucky and may be useful for similar 
worksite wellness weight loss programs.   
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Chapter 1 
 
Introduction 
 
Among the leading causes of death in the United States, heart disease, diabetes, 
and obesity-related illnesses are among the top ten (Centers for Disease Control and 
Prevention, 2009).  Many worksites address these issues by implementing worksite 
wellness programming.  “The worksite, where Americans spend roughly one-third of 
their average day, may be the most well-suited environment for health-behavior change 
(i.e., health promotion programs) because of convenience and accessibility” (Astrup, 
McGovern, & Kochevar, 1992, p. 42). Traditional worksite wellness efforts include such 
programs as smoking cessation, stress management, physical activity, and 
nutrition/weight loss.  Weight loss programs within worksite wellness programs are of 
particular interest because of the impact they may have on diabetes, hypertension and 
dyslipidemia; all of which are contributors to heart disease, diabetes, or obesity related 
illnesses.  In order to effectively evaluate a specific worksite wellness weight loss 
program, the evaluation must consider the impact of these three conditions.  
When evaluating worksite wellness programs, return on investment (ROI) is the 
process used to determine if the financial cost of administering the program is paying off 
in return.  In others words, is the program a wise investment?  Worksite wellness ROI is 
not often separated into individual program evaluations, but evaluated as a whole.  
Different studies have attempted to evaluate ROI in different ways; some looking just at 
weight loss programs, others looking at many types of intervention programs.  Astrup, 
McGovern, and Kochevar (1992) looked at health care claims and absenteeism.   
Bungum, Satterwhite, Jackson, and Morrow (2003) assessed only obesity related health 
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care costs and absenteeism.  Renaud et al. (2008) included overall health profiles, 
employee absenteeism and turnover, and qualitative interview data from managers.  
Trogdon, Finkelstein, Reyes, and Dietz (2009) assessed medical costs and absenteeism 
with average weight loss.  The interest of this study is to only evaluate a weight loss 
program, separate from other interventions, and its effect on prescription claims.  Instead 
of conducting a return on investment in dollar amounts, this study hoped to find value on 
the investment. 
Avenell et al. (2004) reported lifestyle modifications are comparable to drug 
treatments in terms of effectiveness, but Gustafson et al. (2009) specifically showed cost 
effectiveness of weight loss compared to life years gained.  Wang et al. (2006) examined 
higher BMIs compared to cost and showed a lower BMI was associated with lower 
healthcare costs.  Finkelstein, Linnan, Tate, and Leese (2009) and Carls et al. (2011) 
completed longitudinal studies comparing weight loss and health care costs, 
demonstrating more weight loss correlated with lower costs.  Hughes, Girolami, Cheadle, 
Harris, and Patrick (2007) also reviewed the cost savings of weight loss in worksite 
wellness programs by checking prescription drug claims of employees in three Fortune 
500 companies and found a decrease in prescription drug usage. These studies all 
demonstrated a reduction in weight led to a reduction in healthcare costs.  The current 
study hoped to find a reduction in weight associated with a cessation of medication, 
showing value.   
Worksites function as a community all on their own, having a particular culture 
specific to the workplace. Individual health behavior changes have been proven to be 
more effective in the workplace than organizational interventions; however, interventions 
aimed at a specific culture can be beneficial (Goldgruber & Ahrens, 2010). Goldgruber 
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and Ahrens concluded that worksite wellness programs must be adapted to the specific 
culture or community for which they are intended, but still be aimed at the individual 
level.  In a study by Renaud, et al. (2008) personalized health promotion programs in the 
workplace were successful.  The UK Health and Wellness program for employees 
conducts a weight loss program entitled Weight Loss Matters (WLM), which is an 
example of the type of program discussed by Goldgruber and Ahrens and Renaud, et al. 
WLM, while aimed at the individual, has been personalized over the duration of the 
program to meet the cultural needs of the UK Community.   
The literature supports utilizing the Transtheoretical model (TTM) of behavior 
change for worksite wellness weight loss programs.  Weight Loss Matters is loosely 
based on the TTM.  While it frames the program, the TTM does not frame the study, 
necessarily.  Johnson and colleagues found, “individualized stage-matched, multiple 
behavior interventions had significant effects on progression to Action/Maintenance for 
healthy eating, exercise, managing emotional distress, and weight among those most at 
risk (i.e., those in pre-action) one year post intervention” (2008, p. 244). This study is 
similar to WLM in that the main goal was weight loss; and the study showed that weight 
loss was sustained post-intervention. Similarly, WLM addresses several health behaviors.  
Logue et al. (2004) found that the longer a person spends in the action or maintenance 
stages of change, the more likely that person is to lose weight successfully. WLM allows 
participants to repeat the program as many times as desired and this can aid in weight loss 
and maintenance of the healthy behavior, thereby being successful.  As Logue et al. 
(2004) pointed out, the longer people are actively losing weight or maintaining their 
weight, the more successful they are with weight loss.  DiNoia and Prochaska (2010) 
examined the decisional balance relationship to stages of change for dietary behaviors.  
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The authors discovered during precontemplation, the cons are higher than the pros and 
during action and maintenance, the reverse is true (DiNoia & Prochaska, 2010).  In other 
words, when a person is considering a change, but has made no attempt at changing, there 
are more negative thoughts toward the behavior than positive ones.  However, when a 
person has taken steps toward the change or is maintaining a change there are more 
positive thoughts toward the behavior than negative thoughts.  Because participants are 
allowed to stay in WLM without a fee as long as they are meeting their goals, more time 
is allowed to build more pros than cons and therefore end in more successful weight loss.  
Participants are more likely to keep the weight off and change their behaviors if they 
accept more pros than cons.  O’Connell and Velicer (1988) pointed out two studies where 
decisional balance pro/con decisions demonstrated a successful behavior change of 
weight loss.  Finally, O’Connell and Velicer (1988) added that the move from 
contemplation to action may be the time most important in terms of decisional balance.  
The TTM has been demonstrated as highly important in changing health behaviors 
related to weight loss and control, particularly the constructs of decisional balance and 
stages of change (O’Connell & Velicer, 1988).  UK Health and Wellness has employed 
the TTM in the development of WLM, but this model lacks sensitivity to the culture of 
the worksite to promote behavior change. 
To address culture in health promotion programming, the ecological model has 
been used and adapted over time.  McLeroy, Bibeau, Steckler, and Glanz (1988) give a 
history of how the model has been adapted and changed over time to not only address the 
individual, but also the individuals support network (family and friends), the social 
environment, community factors, and public policy.  The model was adapted again by 
Bronfenbrenner in 1979 into three main systems: the microsystem, mesosystem, and 
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exosystem and called the socio-economic model.  The idea of this model is that all three 
levels effect each other.  When one changes, the other levels change, too.  The socio-
economic model serves as a better framework for this study.   
Purpose of the Study 
 
The worksite is an opportune place to conduct weight loss programs which can 
have a significant impact on disease, certain causes of death and possibly ROI due to the 
reduced cost of medications for lifestyle behavior changes.  Weight loss programs have 
proven effective in the management of many chronic diseases, including hypertension, 
diabetes, and dyslipidemia.  But, few programs have evaluated the effect of a weight loss 
program or weight loss on specific medications prescribed for weight-related conditions 
such as blood pressure, high cholesterol and diabetes in a worksite wellness environment.  
Astrup, McGovern, and Kochevar (1992), Bungum, Satterwhite, Jackson, and 
Morrow (2003), Renaud et al. (2008), and Trogdon, Finkelstein, Reyes, and Dietz (2009) 
all show promise in demonstrating the cost effectiveness and positive health effects of 
worksite wellness weight loss programs, but further research needed to be conducted. 
Determining the effectiveness of the worksite wellness weight loss program at UK 
needed to be researched, as it had yet to be evaluated and had collected enough data for 
analysis.   
The purpose of this study was to determine the effectiveness of the worksite 
wellness weight loss program called Weight Loss Matters for employees at the University 
of Kentucky.  More specifically, the purpose of this study was to measure the effect of 
Weight Loss Matters on prescription claims, weight loss, and food diary compliance’s 
effect on weight loss from June 2006 to December 2011.   
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Research Questions/Hypotheses 
 
The following are the research questions and research hypotheses: 
1. Will UK employees who complete one 10-week session of WLM cease taking 
blood pressure medication six months after WLM compared to those who did not 
complete one session of WLM?   
2. Will UK employees who complete one session of WLM cease taking blood 
pressure medication 12 months after WLM compared to those who did not 
complete one session of WLM?   
3. Will UK employees who complete one session of WLM cease taking diabetes 
medication six months after WLM compared to those who did not complete one 
session of WLM?   
4. Will UK employees who complete one session of WLM cease taking diabetes 
medication 12 months after WLM compared to those who did not complete one 
session of WLM?   
5. Will UK employees who complete one session of WLM cease taking cholesterol 
medication six months after WLM compared to those who did not complete one 
session of WLM?   
6. Will UK employees who complete one session of WLM cease taking cholesterol 
medication 12 months after WLM compared to those who did not complete one 
session of WLM?   
7. What is the attendance compliance rate that best affects weight loss after the first 
session? 
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8. Is there a statistically significant relationship between percent body weight lost in 
UK employees and compliance rate after one session of WLM controlling for 
sex? 
9. Is there a statistically significant relationship between body weight lost in UK 
employees and food diary compliance in UK employees who completed one 
session of WLM? 
10. Will physical activity level, sex, food diary compliance, weight loss goal, and age 
predict a change in weight for UK employees who completed WLM? 
11. Will food diary compliance, physical activity level, sex, age, weight loss goal, and 
weight change predict a change in blood pressure prescription claims six or 12 
months after one session of WLM? 
12.  Will food diary compliance, physical activity level, sex, age, weight loss goal, 
and weight change predict a change in cholesterol prescription claims six or 12 
months after one session of WLM? 
13. Will food diary compliance, physical activity level, sex, age, weight loss goal, and 
weight change predict a change in diabetes prescription claims six or 12 months 
after one session of WLM? 
Hypotheses: 
1. Hypothesis 1: UK employees will cease taking blood pressure medications six 
months after completing one session of WLM compared to UK employees who 
did not complete one session of WLM.   
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2. Hypothesis 2:  UK employees will cease taking blood pressure medications 12 
months after completing one session of WLM compared to UK employees who 
did not complete one session of WLM.   
3. Hypothesis 3: UK employees will cease taking diabetes medications six months 
after completing one session of WLM compared to UK employees who did not 
complete one session of WLM.   
4. Hypothesis 4: UK employees will cease taking diabetes medications 12 months 
after completing one session of WLM compared to UK employees who did not 
complete one session of WLM.   
5. Hypothesis 5: UK employees will cease taking cholesterol medications six 
months after completing one session of WLM compared to UK employees who 
did not complete one session of WLM.   
6. Hypothesis 6: UK employees will cease taking cholesterol medications 12 months 
after completing one session of WLM compared to UK employees who did not 
complete one session of WLM.   
7. Hypothesis 7: The higher the attendance rate (attendance of WLM classes), the 
more weight lost in UK employees at the end of the first WLM session.   
8. Hypothesis 8: Percent of body weight lost (weight lost/starting body weight) for 
male and female UK employee will increase with increase attendance compliance 
after one session of WLM.   
9. Hypothesis 9: Percent of body weight lost (weight lost/starting body weight) for 
UK employees who completed one session of WLM will increase with increased 
food diary compliance.   
9 
 
10. Hypothesis 10: A composite of variables: physical activity level, sex, food diary 
compliance, weight loss goal, and age will significantly predict a change in 
percent body weight.   
11. Hypothesis 11: A composite of variables including food diary compliance, 
physical activity level, sex, age, weight loss goal, and percent body weight lost 
will significantly predict a change in blood pressure prescription claims.   
12. Hypothesis 12: A composite of variables including food diary compliance, 
physical activity, sex, age, weight loss goal, and percent body weight lost will 
significantly predict a change in cholesterol prescription claims.   
13. Hypothesis 13: A composite of variables including food diary compliance, 
physical activity level, sex, age, weight loss goal, and percent body weight lost 
will significantly predict a change in diabetes prescription claims.   
Definition of Terms 
For this study, the following terms and their definitions were used: 
 Transtheoretical model-“an integrative framework for understanding how individuals 
and populations progress toward adopting and maintain health behavior change for 
optimal health” (McKenzie, Neiger, Smeltzer, 2005, p.155.) 
Prescription claims-Claims made against the health plan by University of Kentucky 
employees for prescription medications.  These data provide number of doses, days, 
refills filled, and dosage.   
Compliance-For medications, a Medication Possession Ratio (MPR) of 80% is 
considered compliant.  MPR is the number of days’ supply of medication filled divided 
by the number of days of intended treatment.   
10 
 
Completion-Those who attended at least 60% of WLM classes in one session were 
considered completers.  This criterion is used by the WLM program to define completion.  
For food diaries, 60% per session is complete, also. A participant who turns in 6 out of 10 
food diaries in 10 weeks is complete.   
Adherence-“The extent to which a person’s behavior-taking medication, following a diet, 
and/or executing lifestyle changes, corresponds with agreed recommendations from a 
health care provider” (WHO, 2003).  
Significance of the Study 
 
The findings of this outcome evaluation can be further utilized to make changes to 
WLM and other worksite wellness weight loss programs. The results of this study could 
improve programming of future weight loss intervention strategies at the University of 
Kentucky (UK) or other worksite wellness programs.  If weight loss programs of this 
type can be shown to reduce the prescription claims, this could be used as a justification 
for the implementation of more onsite weight loss programs.  Fewer prescription claims 
might mean better health for the individual, lower cost to the employee and the employer.  
The health plan costs would also potentially decrease, reducing premiums across the 
community.  For an organization with a self-funded health plan (like UK), fewer claims 
against that health plan means lower premiums for all users of the plan.   
If successes are found with the weight loss program, participants might be more 
likely to engage in other health promotion programs on the worksite.  Successful weight 
loss can give participants the motivation they need to make other health behavior changes 
through worksite wellness programs such as joining fitness classes, engaging in tobacco 
cessation programs, or completing a health screening.   Building trusted relationships 
with the Health and Wellness staff and other employees through WLM can lend itself to 
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joining other Health and Wellness programs.  Success in WLM and fewer prescription 
claims can act like a springboard to beginning a healthier lifestyle.   
Limitations of the Study 
The research study design is a longitudinal pre-experimental pre/post design.  
Essentially, this is a pre-test/post-test design using several evaluation methods.  There is 
no random sampling because there is only one treatment group and no control.  Since 
there is no control group, the study suffers from some threats to validity.  The first threat 
is history.  Each participant brings in his or her own history that could affect the results.  
For example, previous attempts at weight loss, bariatric surgeries, and psychological 
factors could have an effect on the results, but are beyond the scope of this study.  There 
is no way to control this threat.  The next threat is testing.  Each weekly weigh in could 
be on a different scale or conducted by a different tester.  This variability isn’t captured.  
Finally, instrumentation is a threat.  Participants self-report physical activity upon 
registration as well as food diary entries throughout the sessions.  The result could be an 
increase in physical activity beyond what is their norm or better food choices than were 
actually consumed.   
Additionally, participants are in the study once they begin WLM (starting in 
2006).  This study will look at each participant over time (no matter the amount of 
sessions).  So, a limitation will be that some participants will have attended only one 
session and some will have multiple sessions of WLM with the understanding that those 
who stay in for multiple sessions are likely staying in for weight maintenance.  A final 
limitation is differing medications.  If a participant changes from one category drug to 
another in the same category, he/she are still considered on a medication.  The influence 
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of the drug may be reduced (meaning a decrease in medication in either dosage, amount, 
or days’ supply), but it is beyond this study to determine dosage power difference.   
The possible threats to external validity are social desirability and expectancy 
effect (McKenzie, Neiger, & Smeltzer, 2005). Social desirability is when participants 
answer questions or report certain activities because they think that is the answer the 
researcher wants to hear.  The expectancy effect “is when attitudes projected onto 
individuals cause them to act in a certain way” (McKenzie, Neiger, & Smeltzer, 2005, p. 
324). One way to control this threat is to repeat the program with a variety of participants 
over time.  WLM has done this by conducting the program since 2003 with a variety of 
participants.  The threat of the expectancy effect is reduced by learning to treat everyone 
the same.  Finally, these results may not be generalizable to all worksite wellness weight 
loss programs. 
Conclusion 
 Because worksite wellness programs are an ideal location for weight loss 
interventions that are sustained over time thereby increasing the amount of time spent in 
the action stage of the TTM, they are thus set up for success.  Cost effectiveness is 
important to the institution of higher learning, the health plan, and the individual.  
However, health outcomes are just as important as cost and are the main focus of this 
study.  The literature was lacking research in this area when this study was completed.  
Therefore, WLM at the University of Kentucky needs to be evaluated to determine the 
value of the program in relation to the health outcomes of prescription cessation and 
percent body weight lost.   
 The rest of this dissertation is organized as follows.  In the next chapter, the 
researcher assessed the literature related to the Transtheoretical model, the costs of 
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behavior change compared to drug treatments, hypertension, diabetes, dyslipidemia, the 
socio-economic model, and the costs of worksite wellness.  Chapter 3 describes the 
research design, a description of population, the WLM program, procedures used to 
gather the data, description of measures, and the methods used to analyze the data.  The 
results in Chapter 4 reveal the effects of each analysis, a brief discussion, and the 
limitations of the study.  The main findings of the study were: the more classes attended, 
the more weight lost; the more food diaries completed, the more weight lost; and after 
two sessions of WLM completers were more likely to stop taking their hypertension 
medications than non-completers.  The discussion summarizes the findings, draws 
conclusions, and describes the implications of the study.   
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Chapter 2 
 
Literature Review 
 
 The purpose of this review is to discuss the existing literature regarding the 
Transtheoretical Model (TTM); worksite wellness weight loss programs using the TTM; 
the cost of behavior change compared to drug treatments; weight loss related to 
medication reduction in hypertension, dyslipidemia, and diabetes; the Socio-Economic 
model which is the framework for the study; and costs of worksite wellness.   
 Worksite wellness programs often encompass several behavior change programs 
targeting many health outcomes. Typical worksite wellness programs target nutrition, 
physical activity, tobacco cessation, and stress with outcomes around weight loss, staying 
quit, and improving well-being.  In many places, the Transtheoretical model serves as the 
health promotion model of choice.   
Transtheoretical Model 
Prochaska’s Transtheoretical Model of behavior change is not only popular, but 
useful for many programs including worksite wellness weight loss programming.  Weight 
Loss Matters (WLM) is loosely based on the Transtheoretical Model (TTM) of behavior 
change with the intent of making lifestyle modifications in health behaviors toward 
weight loss. The constructs for this model include: stages of change, decisional balance, 
self-efficacy, and processes of change (McKenzie, Neiger, & Smeltzer, 2005).   
Stages of change.  This theory is based on stages of change toward healthy 
behaviors.  The stages are defined in Table 2.1.  For participants in the precontemplation 
and contemplation stages, awareness, education, and motivation are the key areas of 
action.  Awareness, education, and motivation also help move participants toward the 
preparation stage.  Key actions in preparation might be registering for the program (with 
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fee), attending class, and turning in food diaries.  To move participants into action, 
attendance and food diary completion are important steps to changing behaviors to lose 
weight.  Participants in action are making behavior changes to lose weight and are in 
maintenance when he or she has been doing so for six months or more.  Relapse can 
happen at any stage and participants can then work back through the stages using these 
action steps above.  Termination stage happens when there is no temptation to return to 
old habits that counteract weight loss.   
Table 2.1 
Stages of change 
 
Precontemplation No plans to make change in the next 6 months 
Contemplation Thinking of making changes in the next 6 months 
Preparation Intends to take action in the next 30 days 
Action Overtly making changes in behavior 
Maintenance Have been making changes for last 6 months 
Termination Have no temptation to return to old habits 
Adapted from McKenzie, Neiger, and Smeltzer, 2005 
Decisional balance.  Decisional balance is simply working through the pros and 
cons of changing.  By weighing the pros and cons of the changes necessary to lose 
weight, people can choose to participate in a wellness program such as Weight Loss 
Matters (WLM).  The marketing for the program is one way of highlighting the pros of 
weight loss.  The pros will be different for each person.  For example, a pro might be 
feeling better, fitting into smaller clothes, or improving a medical condition.  The 
professional certifications of the program facilitators (registered dietician, licensed 
dietician) is also a pro in the decisional balance construct that can persuade participants to 
engage in healthy behaviors for weight loss.  Another pro is the continued support of the 
program with other employee based health and wellness programs.  
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Processes of change.  Processes of change are consciousness raising, dramatic 
relief, self-reevaluation, environmental reevaluation, self-liberation, helping 
relationships, counterconditioning, reinforcement management, stimulus control, and 
social liberation (McKenzie, et al., 2005).  These processes are all activities that people 
use to work through the stages and therefore achieve the behavior change. There are ten 
processes of change included in the TTM (Glanz, et al., 2008) each of which is described 
below and how they are employed in WLM at UK. 
Consciousness raising is defined as “finding and learning new facts, ideas, and 
tips that support the healthy behavior change” and is addressed through the educational 
classes held once per week by the registered dieticians and support of the other 
participants (Glanz, Rimer, & Viswanath, 2008, p. 99).  The common website used 
(OneHub.com) is also a resource for educating the participants, as well as the binders 
issued to them at the beginning of the 10 week session.  Components or topics of the 
education include the exchange system, portion control, reading food labels, and how to 
prepare quick meals. Dramatic relief may also be associated with the support and 
collaboration of other participants sharing stories and personal emotions.  When a person 
shares a negative effect in a group of people with common goals, the effect is transferred 
to the supporting members thereby causing the person to want to change to avoid that 
negative effect. 
Self-reevaluation is “realizing that the behavior change is an important part of 
one’s identity as a person” and is addressed by the facilitators during the sessions and 
also reinforced with the weight loss (Glanz, Rimer, & Viswanath, 2008, p. 99).  The 
facilitators reiterate how important weight loss is and how it can become part of their 
identity.  The weight loss itself is a positive reinforcer to self-reevaluation. 
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Environmental reevaluation is learning how the behavior impacts a person’s 
social and physical circles, either positively or negatively.  By realizing the negative 
impact of being overweight or obese and the positive impact of weight loss, it often 
becomes contagious.  That is, the participant encourages others in their social circles to 
participate, thereby improving their environment for weight loss.  WLM becomes a new 
part of the participant’s social circle as it meets regularly for ten weeks.  The other 
participants become part of the new social grouping.  Also, the healthy options on 
campus (the physical environment) are pointed out and discussed.   
Self-liberation is “making a firm commitment to change” (Glanz, Rimer, & 
Viswanath, 2008, p. 99).  It is a process that happens both during and after the program.  
A participant must decide for him or herself to begin WLM, making some decision for 
weight loss. However, continuing the behaviors associated with weight loss typically 
comes after time, learning, and experience.  
Helping relationships can be found with the facilitators, the other participants, a 
participant’s family, or other social circles.  Any relationship that supports the behavior 
change can be a helping relationship. 
Counterconditioning lessons are also part of once a week educational session held 
by the facilitators.  Counterconditioning is the process of substituting healthier behaviors 
for the unhealthy behaviors (Glanz, et al., 2008).  The dieticians help to identify mindless 
sources of eating and bring a more positive behavior into play to counter any bad eating 
habits. Other topics based on counterconditioning are healthy snack choices and healthy 
options for eating out. 
WLM demonstrates reinforcement management by allowing each participant to 
make both short-term and long-term goals, specific to their own behavior. Because every 
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person is motivated differently, rewards for healthy behaviors will look different for each 
participant.  WLM often hosts challenges within each class for one participant to earn a 
prize each week. The challenges reflect healthy behaviors that help participants work 
toward their goals.  Also, the very act of attending WLM week after week helps to 
reinforce the ideas and actions to make the behavior change.  
Stimulus control is not completely addressed in WLM.  The negative cues cannot 
be completely removed from life, but positive reinforcements can be learned in place of 
negative ones to cue good health behavior. WLM address emotional eating as a topic to 
help control mindless eating, eating out of boredom or an emotional response. 
Social liberation can only happen if the participant’s social circles are also willing 
to make such changes or the social circle itself changes to one that is more supportive.  
Being overweight and obese are world-wide problems, and therefore social norms 
surrounding weight loss are not easily changed. Because WLM is conducted in small 
groups, in a niche culture of a college campus in Kentucky, among university employees, 
social liberation can be accomplished to an extent.   This is another reason the socio-
economic model was used as the framework for the study.  The model takes the different 
interacting levels of microsystem, mesosystem, and exosystem into consideration.  
These processes of change take time to implement and result in change.  
Depending on the participant’s readiness to change, a person may or may not be ready to 
move through any of these processes at one time.  An employee weight loss program 
based on the Transtheoretical model helps people move through the stages of change 
using the above-mentioned constructs.  Many studies are cited below which support using 
the TTM as a basis for worksite wellness weight loss programs.  
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TTM in the Workplace 
Because American workers spend so much time at work, worksite wellness 
programs are an ideal place to implement health promotion programs. Worksites function 
as a community all on their own, having a particular culture specific to the workplace. 
Individual health behavior changes have been proven to be more effective in the 
workplace than organizational interventions (Goldgruber & Ahrens, 2010).  However, 
interventions aimed at a specific culture can be beneficial, according to Goldgruber and 
Ahrens. Their conclusion is that worksite wellness programs must be adapted to the 
specific culture or community for which they are intended, but still be aimed at the 
individual level.  In a study by Renaud et al. (2008) personalized health promotion 
programs in the workplace were successful. WLM has been personalized over the 
duration of the program to meet the cultural needs of the UK community. Time and 
location are one way WLM has been molded over time to fit the UK employee 
community.  Class times are typical lunch hours and after work hours.  Class locations 
are on campus near the center of campus and within the healthcare campus of the 
University.  Another way is to use examples that come from campus or local options 
when discussing healthy choices when eating out.  Also, challenges and competitions 
with WLM are formed around University sports bringing out the “fan” in the participants.  
The literature also supports utilizing the Transtheoretical model of behavior 
change for worksite wellness weight loss programs.  Johnson and colleagues found, 
“individualized stage-matched, multiple behavior interventions had significant effects on 
progression to Action/Maintenance for healthy eating, exercise, managing emotional 
distress, and weight among those most at risk (i.e., those in pre-action) one year post 
intervention” (2008, p. 244). This study also showed that weight loss was sustained post-
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intervention.  This study is similar to WLM in that the main goal is weight loss; 
additionally, WLM addresses several health behaviors, as did this study.  Like the 
research study, WLM also address exercise as a topic and emotional eating as a topic.  
Logue et al. (2004) found that the longer a person spends in the action or maintenance 
stages of change, the more likely they are to lose weight successfully.  Given that WLM 
allows participants to repeat the program as many times as desired, this can aid in weight 
loss and maintenance of the health behavior, thereby being successful.  As Logue et al. 
(2004) pointed out, the longer people are actively losing weight or maintaining their 
weight; the more successful they are with long term weight loss.  DiNoia and Prochaska 
(2010) examined the decisional balance relationship to stages of change for dietary 
behaviors.  They discovered during precontemplation, the cons are higher than the pros 
and during action and maintenance, the reverse is true.  This is reinforced in WLM, with 
maintenance and then termination as the goal.  Participants are more likely to keep the 
weight off and change their behaviors if they accept more pros than cons.  O’Connell and 
Velicer conducted two studies where decisional balance pro/con decisions demonstrated a 
successful behavior change of weight loss (O’Connell & Velicer, 1988).  Finally, 
O’Connell and Velicer (1988) added that the move from contemplation to action may be 
the time most important in terms of decisional balance.  TTM is highly important in 
changing health behaviors related to weight loss and control, particularly the constructs 
of decisional balance and stages of change (O’Connell and Velicer, 1988).  WLM has 
employed the TTM in the UK worksite wellness programming to promote behavior 
change. 
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Behavior Change Compared to Drug Treatments 
Avenell et al. (2004a) concluded that low-fat diets and exercise interventions in 
individuals at risk of obesity-related illness, such as diabetes, are of comparable cost to 
drug treatments.  Their statement is supported by other literature as well, indirectly.  
Though Avenell et al. (2004a) reported comparable costs of drug treatment versus 
lifestyle modifications; many studies reported cost savings through weight loss. 
Specifically, in a study by Gustafson et al.(2009), cost effectiveness was evaluated by life 
years gained compared to the cost of conducting the weight loss program. “The Weight-
Wise intervention cost of $61 per kg lost ($27.72/lb) also compares favorably to costs 
reported by other studies, …” (Gustafson et al., 2009, p. 393).  The life years gained were 
scaled to all costs, indicating the Weight-Wise intervention was effective.  In a study by 
Wang et al.(2006), body mass index (BMI) was reviewed as a linear relationship with 
cost when BMI is 25 or higher.  “Within the BMI range of 25 to 45 kg/m2, medical costs 
and pharmaceutical costs increased $119.7 (4%) and $82.6 (7%) per BMI unit, 
respectively, adjusted for age and sex” (Wang et al., 2006, p. 668).  Because of the linear 
relationship, the dollar amounts can also be thought of in the reverse.  Not only is higher 
BMI associated with higher cost, lower BMI (in the normal range) should have lower 
costs.  A longitudinal study was performed by Finkelstein et al. (2009) on weight loss and 
the associated medical costs.  They found that pharmacy expenditures were significantly 
decreased in the group that lost weight as compared to the control group.  Emphasis in 
this study was placed on the long-term weight loss of employees and not simply short 
term to see the greatest cost savings.  Hughes, Girolami, Cheadle, Harris, and Patrick 
(2007) also reviewed the cost savings of weight loss in worksite wellness programs by 
reviewing prescription drug claims of three Fortune 500 companies (N = 512).  “The 
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number of participants taking prescription drugs decreased from 48 to 39 (19%) between 
baseline and 1-year post intervention in a subgroup of 61 participants” (Hughes et al., 
2007, p. 1215).  After applying a current (to the time) annual drug cost average, they 
estimated that this could result in a $2382 decrease per participant.  This is about a 50% 
savings (Hughes et al., 2007). Though these results are positive, such a small sample size 
could be limiting.  Carls, Goetzl, Henke, Bruo, Isaac, and McHugh (2011) conducted a 
longitudinal study of the Johnson & Johnson Corporation and the impact of weight gain 
or loss and health care costs.  This study had major significance as it was one of the first 
to use both longitudinal data and find significant savings with weight loss.  They found 
“Employees who added weight risk (moved from BMI < 30 kg/m2 to BMI > 30 kg/m2) 
increased their average annual medical costs to $1267, about $982 (95%CI: 255-$1710) 
more than employees who remained at lower risk, whose cost increased an average of 
$285 each year” (Carls et al., 2011, p. 11).  In addition, those who gained weight risk also 
increased their health care costs by 9.9% (Carls et al., 2011).  
Part of the picture of drug costs includes compliance and adherence to the 
prescribed therapies.  In 2001, the World Health Organization (WHO) launched a global 
initiative to study and make recommendations for long-term adherence.  Their work 
group chose ‘adherence’ as opposed to ‘compliance’ to better reflect the patient’s 
agreement with the health care provider’s recommendations (WHO, 2003).  In addition, 
adherence is not only to drugs, but any health-related behavior recommended by the 
health care provider.  This might include taking medication, following a diet, or 
implementing lifestyle changes. For developed countries, the adherence rate of lifestyle 
behavior changes averages 50% and is lower in developing countries (WHO, 2003, p.13).  
Separately, compliance is a term utilized by the pharmaceutical industry and is a 
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calculation of number of days’ supply of medication filled divided by the number of days 
intended treatment (Lucy Wells, personal communication, July 23, 2014).   
Furthermore, the WHO suggests greater incidence of non-adherence in asthma, 
hypertension, diabetes, and HIV/AIDS.  In diabetes, specifically, adherence refers to 
taking medications, self-monitoring of blood glucose, dietary restrictions, regular foot 
care, and ophthalmic exams.  Not only does non-adherence negatively affect the patient, 
but also societal and economic costs, as well.  The worksite would also be affected by the 
above.  
Hypertension 
Hypertension or elevated blood pressure (BP) is specifically linked to overweight 
and obesity.  A review study by Johnson et al., (2006) found that three specific 
interventions demonstrated improvement in medication adherence.  “Although drug 
therapy can effectively lower BP and prevent stroke and heart disease, it does not address 
the underlying causes of elevated BP, including obesity, unhealthy dietary habits, and 
limited physical activity” (Funk, et al., 2008, p. 272).  Therefore, compliance to 
pharmacotherapy may not be the answer to helping cure hypertension.   Lifestyle 
modifications have shown better rates of adherence thereby decreasing hypertension.  
“Weight-loss incorporating lifestyle modifications have been found to decrease resting 
BP [15], and [they] found that 4.3-kg loss in weight (4.6%) was sufficient to significantly 
decrease resting SBP by 3 mmHg” (Torres & Nowson, 2007, Discussion, para 1).  
Lifestyle modifications can include increasing healthy dietary habits and physical 
activity, as well as decreasing stress and alcohol intake.  “These lifestyle 
modifications are recommended in non-hypertensive individuals with above –optimal BP. 
For individuals taking BP medication, lifestyle modification is recommended as 
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adjunctive therapy to lower BP” (Appel et al., 2003, p. 2004).  These also happen to be 
the same lifestyle modifications recommended to decrease risk of diabetes and cancer.   
Other studies have shown similar results.  Miller et al. (2002) noted that 
comprehensive lifestyle changes can be powerful interventions for those who use blood 
pressure medication.  In a weight loss study, Horvath et al. (2008) discovered those who 
lost weight needed less medication than the non-weight loss groups.  Not only did 
medication need decrease, other studies found a decrease in BP with adjunctive therapies.  
Torress and Nowson (2007) noted a 2.8 + 1.4 mmHg decrease in systolic blood pressure 
with weight loss.  Alcohol restriction and relaxation therapy proved to lower BP 
(Blumenthal et al., 2002).  Appel et al. (2003) and Blumenthanl et al. (2002) 
demonstrated that when lifestyle modifications are combined there is a greater and more 
significant effect than one intervention alone.  
Diabetes 
Several studies have demonstrated lifestyle modifications can positively affect 
glycemic control, perhaps even better than pharmacological therapy.  However, there has 
been little evidence to show a removal of medication using lifestyle modifications alone.  
Lifestyle modifications include behaviors such as weight loss, physical activity, and 
healthier food choices.  Weight loss is the key lifestyle intervention most greatly 
associated with decreasing risk and key markers for diabetes.   A recent study reported 
“In overweight and obese individuals with type 2 diabetes, weight loss is associated with 
improvements in risk factors” (Horton, Silberman, Davis, & Berria, 2010, p. 1759).  
“Changes in body weight were significantly associated with reductions in A1C” (Horton 
et al., 2010, p. 1761).  A person’s risk of diabetes increases 9% with every 1 kg of weight 
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gain, according to Mokdad et al. (2000).  Again, (Hamman et al. (2006)) suggested 
weight loss had more of an impact on diabetes than diet or physical activity.   
According to studies by Aucott (2008); Delhanty (2002); Elhayany, Lustman, 
Abel, Attal-Singer, and Vinker (2010); Fujioka (2010), Albu et al. (2010); Eakin et al. 
(2010); and Kempf, Kruse, and Martin (2010), the benefits of weight loss on diabetes are 
reduction of risk and specific markers.  Albu et al. (2010) studied metabolic changes in 
type 2 diabetics after 1 year of diet and exercise interventions and found significant 
improvements in insulin sensitivity, fasting glucose, and circulating free fatty acids 
among other results.  Delahanty (2002) made the point that even a small amount of 
weight loss can show improvements in diabetic markers.  Elhayanay and colleagues 
(2010) studied an Israeli population and repeated the same results: that weight loss 
improves type 2 diabetes.  “In these studies some weight loss (3-5 kg) was associated 
with a reduced risk of developing diabetes when compared with the weight-stable group, 
by >10% (upper CI)” (Aucott, 2008, p. 55-56.)   Kempf et al.(2010) and colleagues 
reiterated the effectiveness of lifestyle modifications for type 2 diabetes.  Participants 
who completed their study had a significant reduction in weight, BMI, waist 
circumference, HbA1c, systolic and diastolic blood pressure, and LDL cholesterol.  In 
addition, depression was decreased in this group, as well.  After studying the correlation 
between weight loss and HbA1c, Kempf et al. found “a weight loss of 1 kg was 
associated with a mean reduction of 0.05% HbA1c” (2010, p. 550). 
Aucott went on to say “evidence is now emerging that lifestyle interventions are, 
in the long term, more effective in reducing the risk of developing diabetes than using the 
diabetes mellitus-specific drug Metformin” (2008, p. 56).  In this systematic review, the 
26 
 
conclusion is that diet, physical activity, and behavior therapy are effective for long term 
intentional weight loss.   
Dyslipidemia 
The risk factors that contribute to dyslipidemia include: genetics, ageing, diabetes, 
smoking, sedentary lifestyle, poor dietary habits, and overweight or obesity (CDC, 2010).  
Again, obesity is the major risk factor in dylipidemia as previously shown in the other 
two conditions.  “The dyslipidemia of obesity is typically associated with insulin 
resistance, including higher concentrations of fasting triglycerides and lower 
concentrations of HDL cholesterol” (Hernandez et al., 2010, p. 578.)   
To correct dyslipidemia in persons with metabolic syndrome, weight loss is the 
best first choice (Grundy et al., 2006).  Harman, Leeds, and Griffin (2008) compared an 
energy restricted diet plus two eggs per day compared to the same energy restricted diet 
and found that both groups had a decrease in LDL cholesterol.  They attributed this 
decrease to weight loss and suggested an increase in LDL was counter-effected by the 
weight loss.  Pooblan et al. (2007) studied long term outcomes in the obese and found a 
linear relationship between weight loss and cholesterol.  They went on to say, “this 
suggests that every 10 kg of weight loss may result in an expected drop of 0.23 mmol/L 
in cholesterol for a person with obesity” (Pooblan, 2007, p. 49). Santosa, Demonty, 
Lichtenstein, and Jones (2007) found cholesterol decreased with weight loss in women 
due to changes in cholesterol metabolism. Weight loss was associated with lower LDL 
cholesterol and increases in HDL or good cholesterol. Gustafson reported the women in 
the study improved their weight, systolic blood pressure, BMI, and YLL reduction (years 
of life lost) (2009).  She added that those who attended more sessions had greater 
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improvements, making the case for attendance compliance (a majority of classes) among 
weight loss individuals.  
The evidence is that weight loss improved cholesterol levels, among other 
measurements, over time.  In 2004, Pooblan and colleagues showed that weight loss does 
in fact have long term effects on cholesterol.  Even more recently, Meckling and Sherfey 
found that total cholesterol was decreased by a controlled diet and exercise as well as a 
high protein diet.  Triglycerides were decreased in the high protein plus exercise group.  
All four groups (control, control plus exercise, high protein, and high protein plus 
exercise) lost weight, improved BMI, BP, and waist and hip circumference, indicating the 
efficacy of weight loss and exercise on cholesterol (2007).  Matsuo et al. (2010) found 
weight loss improved many metabolic factors.  However, the significant finding was that 
HDL cholesterol improved after two years of maintaining lost visceral abdominal fat 
levels.  The mean values for triglycerides, glucose, and total cholesterol/ HDL ratio were 
all lower after two years, as well as with weight loss.   “After 4 mo of active weight loss, 
the CHO group had significant reductions in TC, LDL-C, and TAG” (Layman et al., 
2009, p. 519); however, these reductions were not sustained in the long term (12 mo).  
“After 4 mo, the PRO diet resulted in lower TAG, increased HDL-C, and improved 
TC:HDL-C and TAG:HDL-C ratios”(Layman et al., 2009, p. 519).  These changes were 
sustained at 12 months. The studies just described all indicate that weight loss impacts 
cholesterol positively.  “In two studies adding exercise to diet was associated with 
beneficial effects at 12 months for HDL cholesterol (change to 0.1 mmol L-1, 95% CI, 
0.06 to 0.14 mmol L-1) and TGs (change -0.18 mmol L-1, 95% CI, -0.31 to -0.06 mmol 
L-1)”. (Avenell et al., 2004, p. 308-309).  
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Socio-economic Model 
The Socio-Economic Model or ecological model was first introduced as a systems 
theory model by Kurt Lewin in 1951 to explain behavior (Glanz, Rimer, & Viswanath, 
2008).  It has been built upon and adapted by several authors including Barker in 1968, 
Moos in 1980, Bronfenbrenner in 1979, and Glass and McAtee in 2006 (Glanz et al., 
2008).  The theory has been further utilized to guide behavioral interventions by early 
authors such as Skinner and Bandura to others as recently as 2005.  Bronfenbrenner 
(1979) breaks the theory down into environmental systems.  The microsystem includes 
interactions between family members and work groups.  The mesosystem is the physical 
settings of family, work, and school.  The exosystem is the larger systems including 
politics, organizations, and culture.   
The premise of the model is that all levels of an environment work together to 
influence both the person and reciprocally, the environment, as noted by the term 
reciprocal determinism.  “The ultimate purpose of ecological models of health behavior is 
to inform the development of comprehensive intervention approaches that can 
systematically target mechanisms of change at several levels of influence” (Glans, Rimer, 
& Viswanath, 2008, p. 466).  Glanz and colleagues (2008) explained there are four core 
principles of the ecological model: multiple influences on specific health behaviors 
(intrapersonal, interpersonal, organizational, community, and policy levels); these 
influences interact across levels; the model should be behavior specific (using the most 
relevant influences at each level); and interventions that are multi-level are the most 
effective for behavior change.  Simply stated, just because a person is educated for a 
health behavior change does not mean that person will make a change.  In order for 
health behavior change to occur, the total environment must support the healthy behavior.  
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All the levels of influence must change.  For example, intrapersonal-food education, 
interpersonal-support network encouragement, community-institution supported changes, 
and policy-broader policy change to support healthy eating would be needed to affect 
healthy eating.   
The ecological model has been widely used by such entities as the World Health 
Organization’s Global Strategy on Diet, Physical Activity and Health (World Health 
Organization, 2011) and Healthy People 2020 (U.S. Department of Health & Human 
Services, 2010).  The model has been used in tobacco cessation efforts with success and 
researchers have high hopes of applying it to the obesity epidemic “by improving 
environments and policies that drive physical activity and nutrition behaviors” (Glanz, 
Rimber, & Viswanath, 2008, p. 479).  The obvious strength of the model is its use of 
many influences and across levels making interventions at several levels more effective.  
The weakness of the model is not being specific about which influences might have the 
most effect on the behavior change (Glanz et al., 2008).   
A more recent study by Karlsen, Sohagen, and Hjelmesaeth (2013) suggests using 
a “bio-psycho-social model” to study predictor variables on weight loss.  They strongly 
advise using a model that will take all of the above levels of interaction into consideration 
stating “In a real life context, as in a weight loss program, individual physiological and 
psychological factors, often genetically influenced interact with social and environmental 
factors, giving a multitude of individual responses to both the magnitude and rate of 
weight changes” (Karlsen, Sohagen & Hjelmesaeth, 2013, p. 2).   This is a good 
description of how the ecological model works.  
As related to WLM, the ecological model works within the context of UK.  The 
multiple influences on weight loss might include: the particular WLM class, the person’s 
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work group and family/friends network, the institution’s culture, the available food on 
campus, the socio-economic status (SES) of the person, and the physical activity avenues 
available on campus and in the person’s network.  All of these influences interact across 
levels; meaning the food available on campus is influenced by the UK culture and the UK 
culture is influenced by the employees and students of the University and the employees 
and students are influenced by their family and friends network.  There are multiple 
levels of interaction.  The specific behavior is weight loss and there can be changes at 
many of these levels to affect weight loss.   
On the microsystem level, there are several variables: age, sex, BMI, and SES.  
On the mesosystem level, the variables include: family, friends, small groups (work 
groups), and the specific WLM group.  The exosystem includes UK culture, UK as an 
organization, and UK policy.  The University of Kentucky 2009-2014 strategic plan 
comes from the exosystem level.   However, the strategic plan influences the resources 
and supports offered on the other levels. “The five goals of this Strategic Plan identify the 
principal areas of activity in which the talents and resources of the University will be 
invested over the next five years. Under each goal are several objectives, strategies, and 
metrics that make specific the intentions of the University of Kentucky” 
(http://www.uky.edu/Provost/strategic_planning/plan.htm).   There are several ongoing 
supports and resources that are a result of the group programs and strategic plan.  All of 
these systems: microsystem, mesosystem, and exosystem, interact with each other.  There 
are resources and supports that come from each system level and interact upon one 
another.  Variables at each level could not be tested for the scope of this research.   Figure 
2.1 is a diagram of the Socio-economic model as applied to WLM at UK.   
 
31 
 
Figure 2.1 
 
Ecological model in the literature.  McLeroy, Bibeau, Steckler, and Glanz 
(1988) discussed the ecological model and interventions on both the individual and social 
level for health promotion programming.  They suggested five levels of an ecological 
model: intrapersonal, interpersonal, institutional, community, and public policy 
(McLeroy, Bibeau, Steckler, & Glanz, 1988).  Intrapersonal factors include participant 
information such as knowledge, attitude, behavior, self-concept, and developmental 
history.  Interpersonal factors are formal and informal social network, support systems 
such as family, work, and friends.  Institutional factors include formal and informal rules 
and regulations for operation.  Community factors are relationships among organizations, 
institutions, and networks within those communities.  Public policy includes local, state, 
and national laws and policies (McLeroy et al., 1988).   
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Baranowski, Cullen, Nicklas, Thompson, and Baranowski (2003) reviewed 
several research studies utilizing the ecological or social ecological model and suggested 
incorporating cognitive variables into the model to address cues to action, facilitation of 
healthy options by only having certain facilities or food choices available, inhibiting or 
prohibiting a behavior by controlling availability or access, and altering the attractiveness 
of the alternatives.  After reviewing the most popular health behavior change models, 
they stated “behavior-and ecology-based problems require behavior-and ecology-based 
solutions” (2003, p. 38S).  Therefore, they suggested further research to correlate 
causative variables and then focused on procedures that would manipulate the variables 
in order to be the most effective against obesity.  In summary, these authors (2003) 
suggested changing both the environment and individual characteristics for the most 
positive results of behavior change.   
An example of the above idea is by Karlsen, Sohagen, and Hjelmesaeth (2013) 
who found several variables that had direct influence of weight loss at 1 year post 
intervention: weight lost at 12 weeks, age, mental HRQL (emotional quality of life), and 
employment status.  Using these three variables, they found a direct influence on weight 
loss.   
Costs of Worksite Wellness 
Van Dongen and colleagues (2011) completed a systematic review of 18 studies 
on the financial return on investment of worksite health promotion programs targeting 
nutrition and physical activity.  They assessed ROI, net benefits, and benefit cost ratio 
(BCR).  Return was estimated in terms of absenteeism and medical benefits.  Net benefits 
were calculated as benefits (difference of intervention and control groups monetized 
outcome measures) minus costs (difference in program costs between intervention and 
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control groups).  BCR was calculated as benefits divided by costs.  ROI was calculated as 
benefits minus costs divided by costs and multiplied by 100 for a percentage.  The 
researchers made all values in terms of US dollars as of 2010 by standardizing to 
consumer price indices and purchasing power parities (van Dongen, 2011).  In the 18 
studies, interventions included assessment (including self-assessments), 
educational/informational components, behavioral, exercise, environmental and/or an 
incentive component that lasted from six months to five years.  “The financial return was 
positive in 14 out of 21 interventions” (van Dongen et al., 2011, p. 1043).  The 
differences were between randomized control trials and non-randomized studies, where 
the randomized control trials had the most promising results.  Therefore, worksite health 
promotion programs aimed at improving nutrition and physical activity were found to 
have a positive return on investment during the first years of implementation as well as 
reducing employee health care costs (van Dongen et al., 2011).  They also noted the 
intangible benefits go beyond the financial benefits to also increase worker satisfaction 
and improve reputation (van Dongen et al., 2011).   
In summary, the implications of weight loss interventions in the worksite are 
many: improved morale, decreased presenteeism and absenteeism, and improved health 
risk and health care costs to both the employee and the employer.  Regarding employer 
medical costs for employees, there are several conditions or behaviors that are highly 
prevalent and therefore have high associated costs. Table 2.2 below displays data from 
the American Heart Association (2009) indicating prevalence, medical costs, and 
performance loss associated with various heath conditions/behaviors. 
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Table 2.2 
Prevalence Data and Associated Medical Costs and Performance Loss Costs  
Condition/Behavior Prevalence Direct medical costs 
Performance 
loss 
HBP 
High (1 in 3 adults 
have elevated BP) 
Very high ($101 
billion/yr across the 
nation in estimated 
costs) 
Potentially 
high 
Cholesterol 
High (27% of adults 
have cholesterol of 
240 or above) 
Very High ($60 billion 
in medical costs related 
to elevated cholesterol) Unknown 
Exercise-general 
Very High (58% of 
employees are 
sedentary) 
Potentially very high 
(linked to 23% of deaths 
from CHD, stroke, 
colorectal cancer, 
diabetes) Unknown 
Nutrition Very High (80% of 
adults consume too 
much fat; 1/3 are 
overweight) 
Potentially very high 
(related to 5 conditions 
costing $146 billion) 
Unknown 
 Adapted from the AHA (2009) 
A healthy employee costs less than an employee with health conditions.  “The 
truth is healthy employees not only cost less in medical care, they also are more 
functional at work, absent less often, experience fewer injuries, and arrive back on the job 
more quickly after they do get injured” (Lynch, 2002, p. 17) (Thompson et al., 2005).  It 
is not all about the bottom line of cost.  Employees are valuable assets to companies, 
regardless of their ‘price tag’.   
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Chapter 3 
 
Methods 
 
 This chapter includes the methodology by which the study was conducted.  
Included are research design, description of the population and participants, how the data 
were collected, description of measures, description of the program, data coding and 
reorganization, statistical analysis, and categorization.   
Research Design 
 The research design was a quasi-experimental, longitudinal design in which the 
same participants were followed over time, measuring the same variables at different 
intervals.  Data were collected post-hoc from historical records kept by UK Health and 
Wellness staff and UK Healthcare.  Prescription claims data were gathered 12 months 
prior to program participation, six months post program, and 12 months post program.  
This longitudinal design was particularly appropriate given the length of time it takes to 
change health behaviors or to see a decline in medication use (Finkelstein et al. 2009, 
Hughes et al., 2007).     
Description of population 
The population included 14,000 University of Kentucky employees from 2006 to 
2011. The University of Kentucky is a public institution in the city of Lexington, and 
Commonwealth of Kentucky.  The setting for Weight Loss Matters (WLM) was the 
University of Kentucky campus.   
There are several factors within the University that contribute to a distinctive 
culture.  Due to so many different subgroups of employees, each one has unique 
elements. The two main categories of participants were faculty and staff. Staff persons 
typically worked during the day with regular office hours. There are several subgroups of 
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staff, including full-time, part-time, administrative, support staff, and skilled workers.  
The subgroups of faculty included: full-time, adjunct, part-time, and lecturers.  The 
faculty had different schedules than staff persons.  Where a staff person may work the 
typical schedule with a one hour lunch break around noon, faculty persons varied greatly 
with no set hours, thereby, making programming or access to programming difficult.  
Typically, faculty were more educated, had higher incomes, and therefore higher 
socioeconomic status (SES) than a staff person. A higher SES correlates with increased 
health and conversely, lower SES correlates with decreased health (REPORT, 
heathcare.gov). Therefore, faculty were potentially healthier, yet with a more difficult 
programming schedule in a culture different from the rest of the UK community.  The 
staff had the widest range of socio-economic possibilities from top level administration to 
skilled technical workers. All of these factors make for a melting pot of employees 
creating a challenging environment to practice worksite wellness.   
WLM Program Goals and Objectives 
Goals are overarching expectations of what a program will accomplish.  
According to McKenzie, Neiger, and Smeltzer (2005, p. 129), a goal is “much more 
encompassing, or global, written to include all aspects or components of a program, 
provides overall direction for a program, more general in nature, usually takes longer to 
complete, does not have a deadline, usually is not observed, but rather must be inferred 
because it includes words like evaluate, know, improve, and understand, is often not 
measurable in exact terms.” The overall goal of Weight Loss Matters was for participants 
to lose weight through behavioral lifestyle changes learned through educational sessions.  
 Objectives are “more precise and represent smaller steps than program goals-steps 
that, if completed, will lead to reaching the program goal(s)” (McKenzie et al., 2005, p. 
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130). Objectives are broken into hierarchical levels, becoming more specific with each 
level (McKenzie et al., 2005).   
Learning objectives are the first level and focus on steps given to the participants 
to achieve weight loss.  There were three main learning objectives for the student: (1) to 
exhibit nutritional knowledge by food choices reflected on the food diaries, (2) to identify 
cognitive or mental barriers weekly as smaller goals, and (3) to learn the Exchange 
system as reflected in their food choices and recording of food diaries all turned in on a 
weekly basis.  These objectives were assessed by the registered dieticians (RDs) on a 
weekly basis.  Sessions included information on how to read a food label, proper portion 
sizes, mindless or emotional reasons for eating, the importance of exercise, eating smart 
while eating out, and easy meals. These topics help satisfy the first learning objective.  
These were the steps given to the participants to make a lifestyle change and lose weight.   
Behavioral objectives are action oriented.  There were four behavioral objectives 
for WLM: by the end of WLM, participants will be able to apply the nutritional 
information to their lifestyle; utilize a support network through discussions; participate in 
weigh-ins for accountability; and to self-monitor using food diaries.   
Outcome objectives “are the ultimate objectives of a program and are aimed at 
changes in health status, social benefits, risk factors, or quality of life” (McKenzie et al., 
2005, p. 132).  Since the overarching goal of WLM was for participants to make lifestyle 
changes through weight loss, then the outcome objectives included weight loss, 
improvement in health literacy/education, maintenance of weight loss, reduction in risk 
for chronic diseases, decreased morbidity and mortality, and increased quality of life.  
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Program Description 
The Weight Loss Matters (WLM) program was a 10-week weight loss program 
designed for University of Kentucky (UK) employees, retirees, spouses, and sponsored 
dependents.  WLM was designed by the UK Health & Wellness program dietician in 
2003.  Participants were charged a $50 fee; however, they could re-enroll in another 
session of 10-week classes for free as long as they were meeting their weight loss goals 
and felt the program continued to help them.  If the participant did not meet his/her goals 
or dropped out and returned, he/she were only charged $25.  However, by turning in eight 
out of 10 food diaries, a participant could have the $25 fee waived.   
The program was designed for in-person delivery and offered at set times during 
the year in 10-week increments.  Classes were offered three times per week in different 
campus locations.  Classes were held on weekdays with at least one class at lunch time 
and one class in the evening, all covering the same topic.  An online class was offered 
every Wednesday from 12:10-12:50PM; however these data were not included in the 
study due to lack of data for this class.  Participants registered for one of the in-person 
classes, but could attend any class if they missed the meeting time of the one in which 
they registered.  If a participant had to miss a class, he or she could either come to one of 
the other classes offered or continue in WLM for additional cycles. Weekly class topics 
included, but were not limited to: decoding food labels, portion distortion, mindless 
eating, physical activity, eating out, easy meals, weekend warriors, emotional eating, and 
excuses.  Food and exercise diaries were kept by participants and turned in weekly for 
feedback from a Registered Dietician (RD) on a voluntary basis.  Also, each participant 
completed a weekly weigh-in by a trained staff person. Physical activity was encouraged, 
but not required. 
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 In order to help participants with maintenance of the healthy behavior of weight 
loss; the program facilitators used several strategies.  First, the participants set their own 
weight loss goals. Research into WLM by Dr. Maura Scott in UK’s Gatton College of 
Business and Economics revealed that participants viewed their progress more positively 
if they chose a weight range to lose instead of a number of pounds (personal 
communication, 2010).  Therefore, WLM asked participants to set weight range goals.  
Also, the program was self-paced which allowed stronger self-efficacy and therefore 
aided in maintenance.  For example, one participant could lose one pound and feel 
successful while the same week, another participant could lose three pounds and be just 
as successful.  Finally, the strategies taught by the RDs were behavior-change based 
lifestyle modifications. The support found in the group setting also aided in strategizing 
for barriers and issues; thus, aiding in maintenance. If there were participants who 
completed three sessions in a row (three ten-week sessions) they were recognized as 
“Veterans”.  They were asked to share their stories, give advice, and were featured on the 
One Hub website for all WLM participants to recognize.  
 Relapse prevention was addressed on a case by case basis.  Because the classes 
were in person, the RDs were in touch with every participant.  Also, the participants were 
asked to set weekly goals that were not weight related to help stay on track and encourage 
further modifications.  For example, a non-weight related goal could be to sleep eight 
hours three nights per week. In the event a participant were absent two weeks in a row 
with no other communication, the RDs contacted that person to invite him/her back and 
make it easy to get re-involved.  In addition, as previously mentioned, a participant could 
stay in WLM for a second (or more) 10 week session for free if he or she continued to 
meet his or her goal.   
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 This program design demonstrates the Transtheoretical Model approach used in 
WLM.  Moving through the stages of change by weighing pros and cons, understanding a 
participants own self-efficacy, and using the processes of change previously described, 
helps participants to change their behaviors related to weight loss.   
Participants 
 
For the purpose of this research, only UK employees who were on a UK health 
plan were included.  The sample included employees who participated in WLM for at 
least one session between June 2006 and December 2011 for whom there were data. 
Online WLM participants were not included due to lack of data.  Retirees, spouses, and 
sponsored dependents were not included so the results would be more comparable to 
other worksite wellness program evaluations.  There were 591 unique participants 
included in this study.  Participants were either full time or part time employees of the 
University between June 2006 and December 2011. 
Data collection-Records from WLM 
 
WLM records from June 2006 to December 2011 were examined for information 
on UK employees who were on a UK Health Plan and completed an in-person WLM 
class.  These paper records were kept by WLM staff in locked file cabinets or in 
password protected Access database.  Permission to access these records was obtained 
from the Health and Wellness Program Manager.  Institutional Review Board approval 
was obtained prior to data records being accessed.   
Participants were asked to complete a registration form that included several 
variables: sex, date of birth, current height, weight, health concerns, previous attempts at 
weight loss, and physical activity level (see Appendix B).  Then, throughout the ten 
weeks, the facilitators gathered other data.  Out of that data pool, this study utilized 
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weekly weigh-in weight measured in pounds by the program facilitators as well as food 
diary compliance (see appendices C and D).  For this study, food diary compliance was 
defined as six diaries turned in out of the possible ten-week period.  A weekly diary was 
considered complete if it held three days or more of reported food intake.  Likewise, 
attendance completion was defined as participants having attended six classes out of ten.  
Also, the facilitators collected final measurements of height (self-reported) and weight 
(measured). All data were kept confidential by password protection, encryption, and 
using secure servers. 
Data collection -Records from UK Health plan 
 
The prescription claims data were collected from the UK health plan claims 
database by the UK Associate Director for Mental Health Data Management (second 
researcher) at the start date of WLM, 12 months prior to WLM, six months post WLM, 
and 12 months post WLM for each participant for each session.  Prior to the second 
researcher obtaining the records, IRB approval was obtained.  The primary investigator 
supplied the UK Associate Director for Mental Health Data Management the data for all 
participants for all sessions to access the prescription claims, before and after WLM, 
including social security numbers (a unique identifier).  From the prescription claims list, 
the primary investigator worked with a UK Pharmacist to gather a list of drugs that fell 
into three categories: hypertension, cholesterol, and diabetes (see Table 3.1).  
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Table 3.1  
 
Drugs used 
CATEGORY 
ID CATEGORY_NAME Indication 
317 antihyperlipidemic combinations Cholesterol 
316 cholesterol absorption inhibitors Cholesterol 
173 HMG-CoA reductase inhibitors Cholesterol 
252 bile acid sequestrants Cholesterol/Lipids 
241 fibric acid derivatives Cholesterol/Lipids 
174 miscellaneous antihyperlipidemic agents Cholesterol/Lipids 
216 alpha-glucosidase inhibitors Diabetes 
372 amylin analogs Diabetes 
314 antidiabetic combinations Diabetes 
214 biguanides Diabetes 
371 dipeptidyl peptidase 4 inhibitors Diabetes 
293 glucose elevating agents Diabetes 
373 incretin mimetics Diabetes 
215 insulin Diabetes 
282 meglitinides Diabetes 
309 miscellaneous antidiabetic agents Diabetes 
458 SGLT-2 inhibitors Diabetes 
213 sulfonylureas Diabetes 
271 thiazolidinediones Diabetes 
42 angiotensin converting enzyme inhibitors Hypertension 
56 angiotensin II inhibitors Hypertension 
44 antiadrenergic agents, centrally acting Hypertension 
43 antiadrenergic agents, peripherally acting Hypertension 
55 antihypertensive combinations Hypertension 
48 calcium channel blocking agents Hypertension 
274 cardioselective beta blockers Hypertension 
51 miscellaneous cardiovascular agents Hypertension 
275 non-cardioselective beta blockers Hypertension 
155 potassium-sparing diuretics Hypertension 
342 renin inhibitors Hypertension 
156 thiazide and thiazide-like diuretics Hypertension 
53 vasodilators Hypertension 
 
Note: For a more detailed table of specific drugs, their purpose, use, and side effects, see 
Appendix D. 
 
The second researcher then matched the person with the claims, de-identified the 
data, and passed to the primary investigator.  Data analysis was conducted by the primary 
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researcher.  All data were encrypted by the secondary researcher.  In other words, the 
data were translated into another form before being passed to the primary investigator so 
as not to be able to trace the identity of the participants. 
Description of Measures 
The following measures were collected by the WLM program: attendance, 
physical activity, food diary compliance, goal, height, and weight.  These measures were 
collected via the intake form, food diaries turned in, and weekly weigh in sheets.  Body 
Mass Index (BMI) was calculated as weight in kilograms/height in meters2.  Weight loss 
was calculated for each session as starting weight-ending weight.  Percent body weight 
lost was calculated for each session as weight lost/starting body weight. 
Intake form 
A “completer” attended six out of 10 classes.  This number was determined 
because it is the majority of classes, demonstrated by similar research to be the minimum 
effective dose, and is what the staff of WLM determined a completer for program 
purposes (Samuel-Hodge et al, 2009).  Physical activity was measured by self-report in 
number of days per week and minutes per day at the intake.  Physical activity questions 
included “Are you physically active?”, “Number of days per week you are active,” 
“Duration of activity,” “Type of activity” (i.e. walking, aerobics, biking, weight training, 
etc).  These questions are similar to the 2011 Behavioral Risk Factor Surveillance System 
(BRFSS) in asking frequency, duration, and type of activity.  Participants were asked to 
provide a goal using open text response.  These responses were categorized into themes: 
weight loss, maintain, feel better, doctor’s suggestion, or any combination of these. 
Starting height was self-reported at the start and used throughout.   
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Food diaries 
Food diaries were measured by quantity, one for each week of participation 
possible, not the content of the food diaries.  Participants were asked to record all food 
and beverages each day for a week, categorizing them into food groups based on the 
Exchange system.  The diabetic exchange system is a way to organize foods based on the 
amount of carbohydrate, fat, protein, and calories they contain.  There are three main 
categories: carbohydrate group, meat/meat substitute group, and fat group.  All choices in 
each category on the list is equal and can be exchanged for any other on the list 
(http://www.uaex.edu/publications/pdf/fshed-86.pdf . The registered dieticians then 
provided feedback each week to the participants.  Food diaries were encouraged each 
week, but not mandatory for participation in the program.  (See appendices).   
Weekly weigh in 
Weight was measured and recorded each week by trained Health and Wellness 
staff using calibrated digital scales.  This weekly weigh in was also used to determine 
attendance on a weekly basis. 
Health plan measures 
Prescription data were collected from the University health plan database and 
included days’ supply, quantity, and dose for the three conditions: hypertension, diabetes, 
and dyslipidemia starting twelve months prior to participation, six month post 
participation, and 12 months post participation.  First, the secondary researcher pulled all 
prescription claim data for participants in these date ranges.  From these, the primary 
investigator worked with the UK Pharmacist to determine which drugs were used for 
hypertension, cholesterol, or dyslipidemia.  Then, the secondary researcher only provided 
the drugs for the three conditions for each person at each time frame.  By having each 
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medication for each participant at each time frame, this allowed testing of whether or not 
participants ceased taking medications at different intervals.   
Data Coding and Reorganization 
The participant’s sex was coded as male (0) or female (1).  Sessions completed, 
number of classes per session, starting, and ending weight for each class were entered.  
The start and end dates of each session were also recorded.  This allowed the data to be 
changed into subsets on a per session format.  Self-report physical activity was coded as 
yes (1) or no (0); and further described in minimum days per week, maximum days per 
week, minimum minutes per day, and maximum minutes per day.  Height was entered in 
inches.  The prescription data were entered as specific prescriptions 12 months prior to 
start date in milligrams of dose and days’ supply of dose and these same measures again 
at six months and 12 months from start date.  Previous weight loss attempted could be no 
(0) or yes (1).  The participant’s goals were categorized as: weight loss (0), maintain (1), 
look better/feel better (2), doctor’s suggestion/medical reason (3), combination of 0 and 1 
(4), combination of 0 and 2 (5), combination of 1 and 2 (6), and combination of 3 and 0 
(7).  These were the combinations included because these were the combinations present. 
Missing data (N = 3) were corrected where possible by checking ranges and 
correcting key stroke errors but when not possible, they were coded as missing (N = 1).  
For medications that had two drugs in one medication which had two dosages (one for 
each drug), the drug names and dosages were split into separate columns. For example: 
Hydrochlorothiazide-Triamterene with a dosage of 25-37.5 mg was split into 
Hydrochlorothiazide for 25 mg and Triamterene for 37.5 mg.  This was in consultation 
with the UK Pharmacist to better understand each medication.  For goals 0-7, they were 
changed to binary codes either 0 (not present) or 1 (present) for each goal.  The same 
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coding was done for medication category.  For each category of medication, they were 
given a 1 for yes and 0 for no. In order to move all the data into short form, the rows were 
given either 0 or 1 for presence of each health condition at each time frame.  [In order to 
get each individual’s data on one line, the data were manipulated into data sets.] Next, the 
records were concatenated to put all of each person’s individual medications into 
sessions.  This left the dataset in a “per session” format. 
 Additional columns were added as calculations: body mass index (weight in 
kilograms/height in meters2), weight lost (starting weight minus ending weight), and 
percent body weight lost (weight lost/starting body weight).  Age was also calculated 
using starting date minus birth year.  These additional variables were also calculated per 
session and put into the “per session” format. 
Hypotheses and Statistical Analysis 
 
Data collected were both quantitative and qualitative.  The qualitative data were 
categorized and into themes, then converted to quantitative.  All data were then at the 
interval-ratio or categorical level.  Descriptive statistics were calculated to determine the 
means and standard deviations for classes attended, food diaries submitted, weight lost in 
pounds, and age for sessions one through five.  Mean weight lost was also calculated for 
classes one through 10 and then sessions one through five.  SAS software package was 
used for data analysis and significance was determined at the .05 level.  For clarity, the 
hypotheses are repeated below.  
• Hypothesis 1: UK employees who complete one session of WLM will cease 
taking their blood pressure medications 6 months after WLM  
• Hypothesis 2:  UK employees who complete one session of WLM will cease 
taking their blood pressure medications 12 months after WLM. 
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• Hypothesis 3: UK employees who complete one session of WLM will cease 
taking their diabetes medications 6 months after WLM. 
• Hypothesis 4: UK employees who complete one session of WLM will cease 
taking their diabetes medications 12 months after WLM. 
• Hypothesis 5: UK employees who complete one session of WLM will cease 
taking their cholesterol medications 6 months after WLM. 
• Hypothesis 6: UK employees who complete one session of WLM will cease 
taking their cholesterol medications 12 months after WLM. 
For research hypotheses one through six, the dependent variable was the change in 
prescription data claims (specific to each condition).  The independent variable was 
completion of WLM (yes or no).   Both variables were treated as dichotomous: 
completed or not completed and on medications or off medications.  A Chi Square test 
was completed for hypotheses one, two, and six.  A Fisher’s exact test was performed for 
hypotheses three, four and five. 
Because there were no significant values using data from participants who completed 
one session, these same analyses were conducted again for those who completed two 
sessions of WLM.  The analyses were not conducted after three or more sessions because 
the n became too small.   
• Hypothesis 7: The higher the attendance rate (attendance of WLM classes), the 
more weight lost in UK employees at the end of the first WLM session.   
For research hypothesis seven, the dependent variable was weight lost.  The 
independent variable was the attendance rate at WLM (0-10); a continuous variable.  A 
linear regression was conducted to compare those who registered for one session with 
percent lost weight.  After learning there was a positive association between classes 
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attended and weight lost, linear regression was completed to determine if there was a 
certain number of classes at which there was no significance or a certain number at which 
the significance began.    
Hypothesis 8: Percent of body weight lost (weight lost/starting body weight) for UK 
employees who completed one session of WLM will increase at the end of the first WLM 
session compared to starting weight when controlled for sex.   
For research hypotheses eight, the dependent variable was body weight lost; a 
continuous variable.  The independent variable was classes attended; also a continuous 
variable.  A one way ANCOVA was conducted to compare percent weight loss of those 
who completed one session and those who did not complete one session, with sex as the 
co-variate. 
• Hypothesis 9: Percent of body weight lost (weight lost/starting body weight) for 
UK employees who completed one session of WLM will increase with increased 
food diary compliance.   
In research hypothesis nine, the dependent variable was the percent body weight lost, 
a continuous variable.  The independent variable was food diary compliance.  Linear 
regression was performed to test the effect of food diaries on weight loss.  Food diaries 
were broken into three variables: compliance (6 or more), non-compliance (1-5), and 
non-reporting (no data).   The effects of compliance versus non-compliance was 
compared to weight loss.  Then the effects of reporting (either compliant or not) versus 
non-reporting was compared to weight loss.   
• Hypothesis 10: A composite of variables: physical activity, sex, food diary 
compliance, and weight loss goal will significantly predict a change in percent 
body weight.   
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In research hypothesis 10, the dependent variable is the change in percent body 
weight.  The independent variables were: presence of physical activity (yes or no), sex 
(male or female), food diaries (completers, non-completers, and non-reporting), and goal 
(1-7). Physical activity was included as a variable because it was part of the data set 
collected from the intake form.  One week out of ten per session was spent on the topic of 
physical activity.  A multiple regression analysis was completed to determine if the 
independent variables predicted weight loss. 
• Hypothesis 11: A composite of variables including food diary compliance, 
physical activity level, sex, age, weight loss goal, and percent body weight lost 
will significantly predict a change in blood pressure prescription claims.   
• Hypothesis 12: A composite of variables including food diary compliance, 
physical activity, sex, age, weight loss goal, and percent body weight lost will 
significantly predict a change in cholesterol prescription claims.   
• Hypothesis 13: A composite of variables including food diary compliance, 
physical activity level, sex, age, weight loss goal, and percent body weight lost 
will significantly predict a change in diabetes prescription claims.   
In research hypotheses 11-13, the dependent variable was the presence of medications 
(specific to three conditions) at six months post and twelve months post, for each 
condition separately.  The predictor variables included: sex (male or female), age, percent 
body weight lost, presence of physical activity (yes or no), food diary compliance (yes or 
no), goal (1-7), and attendance as a categorical variable (completers or non-completers). 
Logistic regression was performed for each drug category at six months post WLM and 
12 months post WLM.  The logistic regression was repeated treating attendance as a 
continuous variable for each hypothesis.  The analysis was repeated again for those who 
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completed two sessions of WLM for hypertension only. The number of participants who 
completed two sessions and were on cholesterol or diabetes medication was too small to 
test.   
Categorization 
 Most of the analyses were performed only for those who completed one session.  
This was for several reasons.  In hypotheses one through six, comparisons were drawn at 
six months post and 12 months post WLM for each drug as compared to the start to see if 
participants were able to get off of any of their medications after one session.  Though it 
seems logical that the longer a person stays in WLM, the more likely he/she is to come 
off his/her medications, this may not always be true.  Consider the person who completes 
a 10 week session, waits six months, then completes a second 10 week session.  This 
scenario may not bring about drug changes in the same way as a person who completed 
multiple 10 week sessions in a row.  Secondly, those who complete more than one 
session may no longer have a goal of weight loss, but weight maintenance.  In this 
scenario, the weight is not changing so the medications may not change either.  Finally, 
the total n decreases significantly after each 10 week session (Table 3.2).  For these 
reasons, which could not be controlled for, the data were analyzed in hypotheses one 
through six after the first session.  The first six analyses were also conducted after 
completing two sessions of WLM, regardless if these sessions were back to back or 
spread over time. 
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Table 3.2 
Number of participants who completed the corresponding number of sessions 
  N 
1 Session 591 
2 Sessions 273 
3 Sessions 155 
4 Sessions 105 
5 Sessions 76 
6 Sessions 50 
7 Sessions 36 
8 Sessions 27 
9 Sessions 17 
10 Sessions 15 
11 Sessions 12 
12 Sessions 8 
13 Sessions 8 
14 Sessions 6 
15 Sessions 5 
16 Sessions 3 
17 Sessions 3 
 
This chapter describes the methods used to determine if participants stopped 
taking medications, if attendance was correlated with weight loss, if food diary 
compliance was correlated with weight loss, and if any of the variables were predictive of 
weight loss or medication cessation.  Most analyses were conducted after one session of 
WLM and repeated after two sessions of WLM.   
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Chapter 4 
Results 
This chapter presents and briefly discusses the results of the study analyses.  
Included in this chapter are descriptive statistics; Chi Square, Fisher’s Exact, logistic and 
multiple regression for the testing of 13 hypotheses, and discussion of the findings.     
Descriptive Statistics 
There were 591 people in the study (66 men and 525 women) who attended at 
least one session of WLM.  On average, participants were 45 years old (SD 11.17), 
attended approximately five and one half classes (SD 2.88), and completed a little less 
than three-and one-half food diaries  (SD 3.32) in ten weeks.   Participants attended 
anywhere from one class to ten classes in a session.  Completers were defined as those 
who attended six or more classes in a ten-week session (n = 309 for Session 1). The 
average weight loss was almost five pounds in ten weeks (SD 5.86).  The majority (n = 
573) of Body Mass Indexes (BMI) were between 25.77 and 40.17.  Only 18 participants 
(3%) had a BMI of 24.17 or below, putting them into the “normal” category.  The 
categories for BMI are: Underweight = <18.5, Normal weight = 18.5-24.9, Overweight = 
25-29.9, and Obese = 30 or >.  Table 4.1 displays the descriptive statistics for those who 
registered for one session through five sessions.  Figure 4.1 shows BMI distribution for 
the whole sample of 591.   
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Table 4.1 
Descriptive Statistics-Sessions 1 through 5 
 
Session 1 
(N = 591) 
Session 2 
(N = 273) 
Session 3 
(N = 155) 
Session 4 
(N = 105) 
Session 5 
(N = 76)  
 
Variable Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Min Max 
Classes 
Attended 5.60 (2.88) 5.04 (2.73) 4.86 (2.54) 5.6 (2.92) 4.85 (2.62) 0 10 
Food 
Diaries 3.43 (3.32) 2.27 (3.12) 2.21 (3.01) 2.9 (3.65) 2.23 (3.14) 0 10 
Weight 
Loss -4.84 (5.86) -2.03 (3.88) -0.95 (3.45) -2.40 (4.9) -0.83 (4.7) 6.8 -33.1 
Age 
45.28 
(11.17) 
46.55 
(10.98) 
47.46 
(11.03) 
47.51 
(10.83) 
47.29 
(1.30) 22 79 
 
Figure 4.1 
BMI distribution
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 Out of the 591 participants, 57.6% were not on medication at all (average age = 
41.7 years).  With an average age of 52.6 years, 16.4% were on cholesterol medication.  
With an average age of 46 years, 2.3% were on diabetes medication. With an average age 
of 48.8 years, 23.6% were on hypertension medications.  Only eight were on a 
combination of cholesterol and hypertension medications, one on a combination of 
cholesterol and diabetes medications, and two on hypertension and diabetes medications.  
Table 4.2 displays breakdown of the number of participants in each medication category 
in relation to BMI categories. 
Table 4.2 
 
BMI category and medication category totals 
 
 Hypertension Cholesterol Diabetes 
BMI < 24 2 1 0 
BMI 24-30 22 13 1 
BMI >30 43 34 9 
 
It is clear from this table that the higher the BMI, the more medications a 
participant was taking.  More people were taking hypertension medications than both 
cholesterol and diabetes combined. 
Prescription use at six and 12 months post WLM 
To answer the first six research hypotheses, two analyses were completed for 
each: a Chi-Square as well as Fisher’s Exact.  A Chi Square was chosen because the two 
variables were categorical, i.e., either the participant completed WLM or they did not and 
the participant either came off the medications or stayed on the medications. The 
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equation for Chi Squared is X2 = Σ (observed value-expected value)2/expected value.  For 
n values below five, the Fisher’s exact test was applied. The equation for Fisher’s exact is 
(a+b)!*(c+d)!*(a+c)!*(b+d)!/n!*a!*b!*c!*d! where a = non-completers who got off the 
medications, b = non-completers who did not get off the medications, c = completers who 
got off the medications, and d = completers who did not get off  the medications.  N = the 
sample size for each time frame.  Hypothesis 1: UK employees who complete one session 
of WLM will stop taking their blood pressure medications 6 months after WLM.  
Hypothesis 2:  UK employees who complete one session of WLM will stop taking their 
blood pressure medications 12 months after WLM.  These were two-by-two tables 
comparing presence of drug at six months and 12 months post-WLM for completers and 
non-completers for each drug category: hypertension, cholesterol, and diabetes.  Table 
4.3 shows the number of completers who stopped taking medications at different 
intervals with no substitutions.  Tables 4.4, 4.5, and 4.6 are the two by two contingency 
tables for each medication. 
Table 4.3 
Completers (after completing one session) on medications 
 
Completers 
Drug Free Post 
 
Six Months Twelve Months 
N N % N % 
Hypertension  81 17 20.9 23 23.4 
Diabetes  10 3 30.0 3 30.0 
Cholesterol  44 3 6.8 8 18.2 
Note: Completion of program was defined as attendance at six or more classes. 
 This table shows, for example, that 81 participants completed one session of 
WLM and were on hypertension medicine before the program began.  Though the results 
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were not statistically significant, at six months after completing the program, 
approximately 21% of participants stopped taking their hypertension medications and at 
12 months after completing the program, approximately 23% stopped taking their 
hypertension medications.  Similar results were calculated for diabetes and cholesterol 
though the overall number of completers in these groups were lower. 
Table 4.4 
Completers compared to non-completers after one session for hypertension medications 6 
and 12 months post 
Session 1-6 months Got off meds Stayed on meds Total 
Non completers 14 71 85 
Completers 17 64 81 
Total 31 135 166 
    
Session 1-12 months Got off meds Stayed on meds Total 
Non completers 16 69 85 
Completers 23 58 81 
Total 39 127 166 
 
 This table shows that 17 participants stopped taking their hypertension 
medications six months after completing one session of WLM compared to 14 who did 
not complete the program.  At 12 months after, 23 participants stopped taking 
hypertension medications after completing one session of WLM compared to 16 non-
completers.   
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Table 4.5 
Completers compared to non-completers after one session for diabetes medications 6 and 
12 months post 
Session 1-6 months Got off meds Stayed on meds Total 
Non completers 2 16 18 
Completers 3 7 10 
Total 5 23 28 
    
Session 1-12 months Got off meds Stayed on meds Total 
Non completers 2 16 18 
Completers 3 7 10 
Total 5 23 28 
 
 Like the previous table, Table 4.5 shows three participants completed one session 
of WLM and stopped taking diabetes medication six months after, compared to two who 
did not complete one session.  At 12 months, there were three participants who stopped 
taking diabetes medication after completing one session compared to two participants 
who did not complete the program.  Table 4.6 shows similar results, only for cholesterol 
medication and those who completed and stopped taking medication compared to those 
who did not complete the program. 
Table 4.6 
Completers compared to non-completers after one session for cholesterol medications 6 
and 12 months post 
Session 1-6 months Got off meds Stayed on meds Total 
Non completers 7 40 47 
Completers 3 41 44 
Total 10 81 91 
    
Session 1-12 months Got off meds Stayed on meds Total 
Non completers 10 37 47 
Completers 8 36 44 
Total 18 73 91 
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There was no statistical significance between UK employees who completed one 
session of WLM and ceased their blood pressure, diabetes, or cholesterol medications six 
months or 12 months after WLM.   This led to further investigation to see if two sessions 
of WLM would be impactful.   
Because there were no statistically significant associations between UK 
employees who completed one session of WLM and cease taking their medications for 
hypertension, cholesterol, or diabetes, the analyses were repeated to test whether there 
was a significant association between UK employees who completed more sessions of 
WLM and cease taking their medications. Therefore, Chi Square and Fisher’s Exact tests 
were performed again after two sessions of WLM were completed.  These results were 
significant for hypertension drugs six months post-WLM and 12 months post-WLM for 
completers.  The number of observations past two completed sessions was too small to 
conduct data analysis (see Table 4.7).   
 There was a statistically significant association between UK employees who 
completed two sessions of WLM and ceased taking their blood pressure medications six 
months after WLM χ2.  (1) = 5.5547, p < 0.0184 compared to those who did not complete 
two sessions.  There was a statistically significant association between UK employees 
who completed two sessions of WLM and cease taking their blood pressure medications 
twelve months after WLM χ2.  (1) = 11.0929, p < 0.0009 compared to those who did not 
complete two sessions.  For those who completed two sessions, 32% came off their 
hypertension medications six months after WLM.  For those who completed two 
sessions, 50% came off their hypertension medications 12 months after WLM.  
Statistically, participants were more likely to cease taking their medications after 
completing two sessions of WLM than non-completers. 
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Table 4.7 
Completers (after completing two session) on medications 
 
Completers 
Drug Free Post 
 
Six Months Twelve Months 
N N % N % 
Hypertension  28 9 32.1* 14 50.0** 
Diabetes  4 0 0.0 1 25.0 
Cholesterol  14 1 7.1 3 21.4 
Note: Completion of program was defined as attendance at six or more classes. 
*p = <0.05, **p = <0.001 
 Table 4.7 shows the number of completers who were on medications and stopped 
taking medication at six and 12 months after completing two sessions of WLM.  For 
example, there were 28 participants who completed two session of WLM and were on 
hypertension medications prior to starting.  After completing two sessions, 32% stopped 
taking medication and after 12 months, 50% stopped taking hypertension medications.  
Similar results are shown for diabetes and cholesterol medications for those who 
completed two sessions.   
Table 4.8 
Completers compared to non-completers after two sessions for hypertension medications 
6 and 12 months post 
Session 2-6 months Got off meds Stayed on meds Total 
Non completers 5 43 48 
Completers 9 19 28 
Total 14 62 76 
    
Session 2-12 months Got off meds Stayed on meds Total 
Non completers 7 41 48 
Completers 14 14 28 
Total 21 55 76 
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 Table 4.8 displays the two by two contingency tables for completers compared to 
non-completers who stopped taking hypertension medications at six and 12 months post 
WLM.  For example, nine completers stopped taking medications six months after two 
sessions of WLM compared to five non-completers.  These results were statistically 
significant.   
Table 4.9 
Completers compared to non-completers after two sessions for diabetes medications 6 
and 12 months post 
Session 2-6 months Got off meds Stayed on meds Total 
Non completers 4 5 9 
Completers 0 4 4 
Total 4 9 13 
    
Session 2-12 months Got off meds Stayed on meds Total 
Non completers 3 6 9 
Completers 1 3 4 
Total 4 9 13 
 
 Table 4.9 displays the results of the two by two contingency tables for completers 
compared to non-completers at six and 12 months after completing two sessions of WLM 
who stopped taking diabetes medication.  Table 4.10 displays similar results, only for 
cholesterol medication  
Table 4.10 
Completers compared to non-completers after two sessions for cholesterol medications 6 
and 12 months post 
Session 2-6 months Got off meds Stayed on meds Total 
Non completers 3 23 26 
Completers 3 11 14 
Total 6 34 40 
    
Session 2-12 months Got off meds Stayed on meds Total 
Non completers 4 22 26 
Completers 1 13 14 
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Table 4.10 (continued) 
 
Total 5 35 40 
 
There was not a statistically significant association between UK employees who 
completed two sessions of WLM and cease taking their diabetes (n = 4) or cholesterol (n 
= 14) medications six months or 12 months after WLM compared to those who did not 
complete two sessions. Twelve months after two sessions, 25% of completers ceased 
taking diabetes medications and 21.42% ceased taking cholesterol medications. 
For those who completed one session of WLM, a sub-sample of low BMI (below 
30) and high BMI (30 and above) was tested via Chi Square analysis.  Because there 
were only 18 participants in the normal category, a different stop point had to be 
determined.  Therefore, below 30 BMI were compared to above 30.  There was no 
significant difference between groups for those who ceased taking hypertension (n = 81), 
cholesterol (n = 44), or diabetes (n = 14) medications 12 months after one session of 
WLM (see Table 4.11). On average, the low BMI group lost 2.18% body weight and the 
high BMI group lost 3.52% body weight in one session of WLM.  This might be due to 
the low BMI group having such a small n.  There were even fewer participants on 
medications after two sessions, which made analysis unwarranted.   
Table 4.11 
 
12 months after completing one session by BMI group 
 
 Hypertension Cholesterol Diabetes 
 On Off On Off On Off 
Low BMI 18 7 8 2 1 0 
High BMI 40 16 28 6 9 4 
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Attendance and percent body weight lost 
Hypothesis 7: The higher the attendance rate (attendance of WLM classes), the 
more weight lost in UK employees at the end of one WLM session.  For the seventh 
hypothesis, a linear regression analysis was chosen to test if the predictor variable 
(classes attended) accurately predicted the dependent variable (percent weight loss).  
Using classes attended as a continuous variable, the results showed the variable of classes 
attended was significant, F(1,587) =318.60, p = < 0.0001 for percent weight lost. The 
more classes attended, the more weight lost in one session.  This can be seen in the fit 
plot in Figure 4.2 and the equation: Y = a + bX where Y is percent weight lost, a is 
intercept, b is the slope of the line and X is classes attended.   
Figure 4.2 
Fit Plot of classes attended and percent weight loss 
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There were 589 participants who enrolled in one session of WLM with records for 
classes attended.  The fit plot shows classes attended (β =  0.577) is positively associated 
with percent weight lost R2 = 0.35, Pr > [t] of  < 0.0001.  As the number of classes 
attended increased, the probability of weight loss increased.   
The weight loss percent mean is 2.38; meaning people lost an average of 
approximately 2.4% (SE = 0.032) body weight in one 10-week session.  For a 200-pound 
person, this would equal 4.8 pounds per 10-week session.   
Linear regression was repeated investigating each level of classes attended (i.e., 2-
10).  Linear regression modeling indicates that attending four classes or more had a 
statistically significant association with percent weight lost compared to those who only 
attended one class F(9,589) = 39.92, p < 0.001.  The mean percent weight lost per classes 
attended within a 10-week session are shown in Table 4.12.  For a 200-pound person, at 
four weeks, they would have lost 1.4 pounds on average.  This is not as meaningful, 
though it is statistically significant.  For a 200-pound person, at six weeks, they would 
have lost 3 pounds on average.  See table 4.12 for mean percent weight lost per number 
of classes attended and Table 4.13 for estimates.   
Table 4.12 
Percent weight loss per class attended for one session (N=589) 
Classes 
attended Mean (SD) 
1  0.12 (1.05) 
2  0.3 (1.52) 
3  0.35 (1.63) 
4  0.67 (1.84) 
5  1.0 (2.27) 
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Table 4.12 (continued) 
6  1.48 (2.38) 
7  1.48 (2.0) 
8  2.36 (2.55) 
9  2.79 (3.11) 
10  4.69 (3.34) 
 
Table 4.13 
Multiple regression modeling the association of percent body weight lost with number of 
classes attended as predictor variables (n=589) 
Predictor Variable Estimate (SE) 
Intercept 20.88 (2.57) 
2 classes attended -0.46 (0.44) 
3 classes attended -0.39 (0.40) 
4 classes attended -1.24 (0.43)* 
5 classes attended -1.53 (0.43)** 
6 classes attended -2.06 (0.40)** 
7 classes attended -1.80 (0.43)** 
8 classes attended -3.67 (0.43)** 
9 classes attended -4.08 (0.42)** 
10 classes attended  -5.42 (0.40)** 
Note: * p = 0.0004, ** p = <0.001 
Attendance and percent body weight lost-Sex 
Hypothesis 8: Percent of body weight lost (weight lost/starting body weight) for 
UK employees who completed one session of WLM will increase at the end of the first 
WLM session compared to starting weight when controlled for sex.  To test the eighth 
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hypothesis, an analysis of co-variance was used on 586 records of those who enrolled in 
one session of WLM who had sex recorded.  An ANCOVA was chosen because the 
predictor variable (attendance) was categorical.  The dependent variable was percent 
weight lost.  Sex was the co-variant.   The main effect of sex yielded an F ratio of 
F(2,583) =1.05, p = 0.31, indicating that sex was not significant.  The equation used was: 
Y = b0 + b1X1 + b2X2 where Y is percent weight lost, X1 is female, X2 is classes attended 
and b is the change in Y relative to the change in X.  Table 4.14 displays the results of 
this analysis. 
Table 4.14 
Analysis of Co-variance for sex on weight loss 
 Estimate (SE) Pr > [t] 
Intercept -0.592 (0.339) 0.082 
Female  -0.303 (0.295) 0.305 
Male 0.000  
 
Food diaries and percent body weight lost 
Hypothesis 9: Percent of body weight lost (weight lost/starting body weight) for 
UK employees who completed one session of WLM will increase with increased food 
diary compliance.  An analysis of covariance for the ninth hypothesis used 454 records as 
this was the number who enrolled in one session and had data for food diaries.  An 
ANCOVA was chosen to determine if a statistically significant difference between food 
diary compliance and the dependent variable (percent weight loss) were present for those 
who completed one session compared to those who did not complete one session.  The 
covariate is attendance; whether participants completed six or more classes (compliant) 
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or less than six classes (non-compliant).  The model showed the effect of food diaries 
completed was significant F(2,451) =116.85, p = <0.0001 for those who attended six or 
more classes.  The more food diaries completed the more percent body weight lost.  This 
can be seen in the fit plot in Figure 4.3 and the equation: Y = b0 + b1X1 + b2X2 + b3X3 
where Y is percent weight lost, b0 is the slope of the line and X1 is food diary compliance, 
X2 is attended, and X3 is not attended.  
Figure 4.3 
Fit plot of food diary compliance and percent weight loss for compliers and non-
compliers 
 
 To test the hypothesis another way, two linear regressions were conducted.  The 
food diary compliance variable was divided into three variables: compliance (6 or more 
food diaries), non-compliance (0-5 food diaries), and non-reporting (missing data).  The 
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non-reporting variable could be between 0 and 10 food diaries, just not reported.  The 
first linear regression included food diary compliant (six or more diaries completed) 
compared to non-compliant (N = 586).  The second linear regression included non-
reporting participants compared to reporting (N = 586).  The first model indicates 
compliance was statistically significantly associated with weight loss F(2,585) = 179.43, 
p = <0.001 compared to non-compliance.  The second model shows reporting was 
statistically significantly associated with weight loss F(2, 585) = 184.02, p = <0.001 
compared to non-reporting.   Together these results mean reporting any food diaries is 
better than not-reporting and reporting six or more food diaries was associated with better 
weight loss than reporting five or less.  Table 4.15 displays both model’s estimates and p 
values.   
Table 4.15 
Two regressions modeling food diaries and weight loss 
Model 1 Estimate (SE) Pr > [t] 
Compliant compared to non-compliant 0.82 (0.37) 0.026 
Model 2   
Reporting compared to non-reporting 0.49 (0.20) 0.013 
 
Percent body weight lost and sex, PA, food diaries, and goal 
Hypothesis 10: A composite of variables: physical activity, sex, food diary 
compliance, and weight loss goal will significantly predict a change in percent body 
weight.  A multiple regression was performed utilizing weight loss percent as the 
dependent variable and sex, physical activity (dichotomous), food diary compliance 
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(continuous), and goal (categorical) as the predictor variables in 152 observations using 
the equation: Y = b0 + b1X1 + b2X2 + b3X3... where Y is the dependent variable (weight 
loss percent), b is the slope, and X2, X3… represents each predictor variable.  Table 4.16 
displays the number of participants in each goal category.  The analysis found that 
physical activity (p = 0.01) and food diary compliance (p < 0.0001) were significant 
predictors, but not sex or goal R2 = .27, F(4,147) = 13.41, p < 0.0001. 
Table 4.16 
Number participants in each goal category 
Goal 0-Weight Loss 351 
Goal 1- Maintain 1 
Goal 2-Feel better/look better 21 
Goal 3- Doctor’s suggestion/medical reason 1 
Goal 4- 0+1 1 
Goal 5- 0+2 40 
Goal 6- 1+2 0 
Goal 7 - 0+3 1 
 
Multiple regression was repeated for one session enrollees another way.  The 
second linear regression compared those who attended (six or more classes) and dummy 
variable, who were food diary compliant (six or more diaries) and dummy variable, food 
diary reporting and dummy variable, physical activity reported and dummy variable, and 
each of seven goals with corresponding dummy variables.  The model was significant F 
(10, 350) = <.001 and when physical activity was not reported, these cases were not 
included.  Attending six or more classes and having a goal of “doctor’s 
69 
 
suggestion/medical condition” were both significant for percent weight lost in the second 
model.  Physical activity was not significant in this model, though it was in the first 
model (p = 0.10).  Table 4.17 shows which variables significantly predicted weight loss 
percent for this second model.  
Table 4.17 
Multiple regression modeling the association of percent body weight lost with potential 
predictor variables (N=350) 
Predictor Variable Model 2  
Estimate (SE) 
Intercept 4.55 (7.93) 
Physical activity reported -0.34 (0.20) 
Attended six or more 0.88 (0.24)** 
Food Diary compliant              0.43 (0.56) 
Food diary Reporting       0.30 (0.21) 
Goal 0 “Weight loss” -1.79 (1.81) 
Goal 1 “maintain”                    N/A 
Goal 2 “Feel better/look better”    -1.37 (1.86) 
Goal 3 “Doctors suggestion/medical 
reason”           
9.80 (2.55) *** 
Goal 4 = 0+1                                   -3.54 (2.56) 
Goal 5 = 0+2                                  -1.69 (1.83) 
Goal 6 = 1+2                                  -2.26 (2.55) 
Goal 7 = 0+3                                  0 
Note: * = p < .05, ** = p <.001, *** = p < .0001 
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  Table 4.17 indicates the estimate (SE) for each predictor variable on weight loss.  
The goal of “doctor’s suggestion/medical reason” was statistically significant though 
there was only one participant in this model with this goal.   
Hypertension  
Hypothesis 11: A composite of variables including food diary compliance, 
physical activity level, sex, age, weight loss goal, and percent body weight lost will 
significantly predict a change in blood pressure prescription claims.   
The first logistic regression analysis of 88 observations was conducted with the 
dependent variable being presence of hypertension medications six month post-WLM 
(dichotomous).  Sex, physical activity, classes attended (continuous), food diary 
compliance (continuous), goal, age, and percent body weight lost were predictor 
variables.  The number of participants used in this analysis was 88 because this was the 
number of participants who reported hypertension medication use data at twelve months 
prior to WLM.  Logistic regression was chosen because the dependent variable (presence 
of medication six months post-WLM) was dichotomous and this analysis was chosen to 
determine the relationship of the six variables to the dependent variable.  The model was 
not significant, indicating the variables did not have a statistically significant relationship 
Pr > χ2 = 0.083.  The equation for the model is p = exp(b0=b1X1+b2X2…)/1+ exp 
(b0=b1X1+b2X2…) where the p is the expected probability that the outcome is present, the 
X represents the predictor variables, and the b represents the coefficients.   
 The model was repeated with the dependent variable being presence of 
hypertension medications 12 month post-WLM and sex, presence of physical activity, 
classes attended (continuous), food diary compliance (continuous), goal, age, and percent 
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body weight lost as predictor variables.  The model was not significant, indicating the 
variables did not have a statistically significant relationship Pr > χ2 = 0.23.   
 A second regression analyses of 88 observations was conducted using sex, 
physical activity reported or not, goal one through seven and corresponding dummy 
variables for each as predictor variables and getting off hypertension medications six 
months after one session of WLM.  This model was repeated using sex, physical activity 
reported or not, goal one through seven and corresponding dummy variables for each as 
predictor variables and getting off hypertension medications 12 months after one session 
of WLM.  Classes attended was a continuous variable for both models.  Neither model 
was statistically significant as shown in table 4.18.   
Table 4.18 
Logistic regression modeling each predictor variables effect on stopping hypertension 
medication six and 12 months post WLM 
 6 Months Post 12 Months Post 
Predictor variable Estimate(SE) Estimate(SE) 
Intercept   7.09 (405.3) 1.11(1.75) 
Sex-male 0.25 (0.43) 0.64 (0.42) 
PA Start   0.47 (0.37) -0.13 (0.28) 
Classes _attended -0.18 (0.19) 0.07 (0.16) 
Food diary compliance -0.15 (0.15) -0.02 (0.11) 
Goal 0      5.07 (63.24) -0.43 (0.92) 
Goal 1 0 0 
Goal 2       0.26 (147.2) -12.17 (379.6) 
Goal 3      10.75 (382.9) 14.22 (690.6) 
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Table 4.18 (continued)   
Goal 4 0 0 
Goal 5     0 0 0 
Goal 6  0 0 
Goal 7 0 0 
Age 0.06 (0.03) -0.05 (0.03) 
Weight Loss Percent 0.29 (0.17) -0.01 (0.13) 
 
A final regression was conducted with the same variables as the previous analyses 
for those who completed two sessions (n = 45) of WLM.  The two sessions model had the 
best fit (AIC = 37.34, SC = 39.15), though none of the variables were statistically 
significant for ceasing medication likely due to the low n.    
Cholesterol  
Hypothesis 12: A composite of variables including food diary compliance, 
physical activity, sex, age, weight loss goal, and percent body weight lost will 
significantly predict a change in cholesterol prescription claims.  A logistic regression 
was completed using 48 records with the dependent variable being presence of 
cholesterol medications six months post-WLM and sex, presence of physical activity, 
classes attended (continuous), food diary compliance (continuous), goal, age, and percent 
body weight lost as predictor variables.  Forty-eight records were used as this was the 
number of participants who were on cholesterol medications and had data recorded at 
twelve months prior to WLM.  The model was used again at 12 months post-WLM.  The 
models were not statistically significant Pr> χ2 = 0.44 and Pr> χ2 = 0.64, respectively.  
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This is likely due to the low n.  This model was considered again after two session of 
WLM, however the n was too low to complete the analysis. 
Diabetes  
 Hypothesis 13: A composite of variables including food diary compliance, 
physical activity level, sex, age, weight loss goal, and percent body weight lost will 
significantly predict a change in diabetes prescription claims.  A logistic regression 
analysis of 12 observations was conducted with the dependent variable being presence of 
diabetes medications six month post-WLM and sex, presence of physical activity, classes 
attended (continuous), food diary compliance (continuous), goal, age, and percent body 
weight lost as predictor variables.  Twelve observations were used as this was the number 
of participants who were on diabetes medication and had values recorded twelve months 
prior to WLM.  The same model was used for a second analysis after 12 months.  Neither 
model was statistically significant, likely due to the low N Pr > χ2 = 0.15 and Pr > χ2 = 
0.44.  This model was also considered again after two sessions, but not able to be 
completed due to the low n.  
Discussion 
There was a large difference between the number of men (66) and women (525) 
included in the data set.  Research has indicated women are greater users of healthcare 
systems (Kramer, H.U., et al. 2012;  Shalve, V., Chodick, G., and Kokia, E., 2005; Roy, 
K. and Chaudhuri, A. 2008).  This may account for the disproportionate number of males 
verses females.  Out of the total sample of 591 only 42.4% of participants were on any of 
the three categories of medication at all.  Only 10 participants had co-morbidities or were 
on more than one category of medication.  The average age of those on medications was 
50.2 years and those not on medications was 41.7 years. This is in line with national 
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trends.  According to Gallup, 52% of Americans report taking prescription medication 
while 48% report taking no prescription medications 
(http://www.gallup.com/poll/20365/Half-Americans-Currently-Taking-Prescription-
Medication.aspx).  For those 30-49, 40% report taking prescription medications while for 
those 50-64, that number increases to 61%.  In the 65 and over group, it rises to 88% on 
medications.     
For each of the 13 research questions, each question was asked after one session 
of WLM and after finding no statistical significance the hypotheses were tested again 
after two sessions of WLM.  For some analyses, two sessions of WLM were found to be 
adequate to find significant changes.   
The first two research questions were similar, the only difference being whether 
the analysis was conducted at six months or 12 months post-WLM.  Hypothesis 1: UK 
employees will cease taking blood pressure medications six months after completing one 
session of WLM.  There was no statistical significance six months after one session, 
therefore the researcher asked the same question after two sessions and found a 
statistically significant correlation between those UK employees who completed two 
sessions of WLM and ceased taking their blood pressure medications six months post-
WLM and 12 months post-WLM.  Though there was no statistically significant 
association after one session, 21% of participants ceased taking their medications after 
six months and 28% ceased taking them after 12 months.  A study by Miller et al (2002) 
demonstrated a large reduction of blood pressure lifestyle modifications, results similar to 
medication therapy, for reducing blood pressure.  Though their study was short (only 9 
weeks), the significantly lower blood pressure was extrapolated to assume stopping 
medications if continued long term.  The results of the current study demonstrated 
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subjects stopping blood pressure medications with weight loss after two sessions.   
Hughes, Girolami, Cheadle, Harris, and Patrick (2007) found after 26 or 52 weeks in a 
worksite wellness weight loss intervention, prescription claims decreased 44% in a 
subgroup of 61, similar to the current study.  Though the current study measured data for 
five years, the number of participants who stayed in WLM for two sessions was 155 and 
of those only 76 were taking blood pressure medications.  While the other studies lacked 
longitudinal data, the current study demonstrated participants ceased taking their blood 
pressure medications six and 12 months after 20 weeks of a weight loss program.  These 
20 weeks may or may not have been continuous as previously described.  One session 
was 10 weeks and a participant may have waited any amount of time before starting 
again or their enrollment may have been continuous without gaps. Regarding the 
Transtheoretical Model, the participants who only stayed in one session (10 weeks), 
might have been relapsing from action or they may have achieved their goal and moved 
on to termination or maintenance.  On the other hand, it is possible that those who stayed 
in for two sessions or more might have relapsed and come back to action or stayed in 
action throughout the whole 20 weeks.   
In the same way, the third and fourth research questions were similar to one 
another, conducting analysis at six months and 12 months post-WLM.  Hypothesis: UK 
employees will cease taking diabetes medications six months after completing one 
session of WLM.  Again, there was no statistical significance six months or 12 months 
after WLM and the researcher tested again after two sessions of WLM.  There was still 
no statistically significant association.  In a systematic review by Aucott (2008) and 
another by Fujioka (2010), they highlighted several studies that showed a reduction in 
blood glucose levels is highly associated with weight loss.  None of these studies showed 
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a complete removal of medications and suggested longer termed studies to see if there 
were any effects on medication use.  This current research has five years’ worth of data, 
but the actual number of participants who stayed in WLM for more than two sessions (20 
weeks) was 155 and of those, only 13 were on diabetes medication.  In addition, the 
current study only measured whether participants ceased taking their diabetes medicine, 
not a reduction in medicine as previous studies had measured. 
Research questions five and six were also similar.  Hypothesis 5: UK employees 
will cease taking cholesterol medications six months after completing one session of 
WLM.  Neither at six months or 12 months after one session of WLM, was there any 
statistically significant association, therefore, the researcher tested the hypothesis again 
six and 12 months after two sessions of WLM and still found no significance.  After six 
months, seven percent who completed two sessions ceased taking medication.  After 12 
months, 21% who completed two sessions ceased taking medication.  The literature 
supports HDL cholesterol improvement after maintaining weight loss for two years 
(Matsuo, 2010).  The current data set had only 40 participants using cholesterol 
medications and staying in the program for two sessions (20 weeks).   
Finkelstein, Linnan, Tate, and Leese (2009) looked at cost savings from all 
medical claims (prescription and otherwise) in a sample of employees from 17 colleges 
across North Carolina, but did not find significant effects for all claims.  They did not 
find significant cost savings for those who lost weight, except for pharmacy claims.  This 
current study partially supports those findings as hypertension medications were stopped 
after two sessions.  Though these numbers are small, these costs can add up over time.  
Regarding diabetes and dyslipidemia, genetics might have influenced the results.  
The average age of the participants was 45 years.  There is potential that medications for 
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these two conditions are not prescribed until later in life.  In this sample, the average age 
of those on medications was 50.2 years while the average age of those not on medication 
was 41.7 which could be why there were no significant findings for diabetes or 
cholesterol medication cessation.  There were relatively few people on medications 
(42.4% on medication). From a larger perspective, health promotion is often about 
keeping the well well and working to move the higher risk participants along the scale 
toward well.  This is a demonstration of that idea.   
The seventh analysis tested the hypothesis: The higher the attendance rate 
(attendance of WLM classes), the more weight lost in UK employees at the end of the 
first WLM session.  The results showed the more classes attended, the more weight lost 
with the weight loss percent mean of 2.4%.  For example, for a 200-pound person, this 
would equal 4.8 pounds lost in one session.  From the descriptive statistics, the average 
attendance for one session was 5.6 classes meaning participants, on average, lost about a 
pound per week per class attended.  Further investigation revealed attending four classes 
was significantly associated with percent weight lost. This could have been due to the 
participants’ readiness to change per the Transtheoretical model (TTM).  After registering 
and paying the fee, the participants were likely in the preparation stage, which is ‘ready 
to take action in the next 30 days’, moving into action ‘overtly making changes in 
behavior’.   However, because stage of readiness was not measured, this assumption may 
not be valid. 
Johnson and colleagues (2008) and Logue et al. (2004) also found that staying in 
the action stage or maintenance stage of the TTM had significant effects on long term 
weight loss.  Two sessions of WLM is 20 weeks, which could be action or maintenance, 
but also might mean there is a relapse.  Like the previously mentioned studies, this study 
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also found that the longer a person attended, the more weight lost.  Staying in WLM for 
two or more sessions had significant effects on long term weight loss.  
The eighth question was the same as number seven only controlling for sex.   
There were no sex differences when comparing classes attended to percent body weight 
lost.  From the sample of 591, 11% were male, 89% female.   
Hypothesis nine: Percent of body weight lost (weight lost/starting body weight) 
for UK employees who completed one session of WLM will increase with increased food 
diary compliance.  There was a significant direct relationship in food diary compliance 
and weight loss.  Food diary compliance together with attendance completion have the 
best case scenario for predicting percent weight loss.  Food diary compliance is a form of 
self-monitoring.  In a systematic review of 22 studies regarding self-monitoring by 
Burke, Wang, and Sevick (2011), 15 studies reported significant associations between 
self-monitoring and weight loss.  The current research supports this same finding.   
The tenth research analysis utilized all the variables into a regression model and 
was computed two ways. The hypothesis was: A composite of variables: physical activity 
level, sex, food diary compliance, attendance, and weight loss goal will significantly 
predict a change in percent body weight.  Though the instrument to collect physical 
activity information was not robust, the variable was included as part of the intake and 
therefore included in the model, though it may affect the results.  The results reinforced 
the finding that attendance and food diaries have a statistically significant relationship on 
weight loss.  One goal had a statistically significant relationship to weight loss; having a 
goal of doctor’s suggestion/medical reason increased the likelihood of losing weight.  
Dixon and his colleagues (2009) conducted a study to uncover motivation to lose weight 
with bariatric surgery.  Their categories for motivation coincided with this research’s 
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variable of goal.  They found 69% choose “to improve a medical condition” or “to 
improve health”.  This is similar to this study’s option of “doctor’s suggestion/medical 
reason”.   
Hypotheses 11-13 were similar in that each tested for a change (off or on) in 
prescription claims for each condition (hypertension, diabetes, and cholesterol) at six 
months and 12-months post with all possible predictor variables using logistic regression 
modeling.  None of the results were statistically significant.  However, since results from 
hypotheses one and two showed two sessions were required for participants to cease 
taking medications for hypertension, these hypotheses were tested again after two 
sessions of WLM.   
The 11th hypothesis was a composite of variables including food diary 
compliance, physical activity level, sex, age, weight loss goal, and percent body weight 
lost will significantly predict a change in blood pressure prescription claims six months 
(and 12 months) post one session of WLM.  There were no significant results after one 
session.  With two sessions, the N = 45, thus making analysis unsubstantiated as there 
were 14 variables in the model.   
The 12th hypothesis was a composite of variables including food diary 
compliance, physical activity level, sex, age, weight loss goal, and percent body weight 
lost will significantly predict a change in cholesterol prescription claims six months (and 
12 months) post one session of WLM.  There were no significant results after one 
session.  After two sessions, the N = 44 which was too small to analyze.   
The 13th question was will food diary compliance, physical activity level, sex, 
age, weight loss goal, and weight change predict a change in diabetes prescription 
claims?  The hypothesis was a composite of variables including food diary compliance, 
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physical activity level, sex, age, weight loss goal, and percent body weight lost will 
significantly predict a change in diabetes prescription claims six months (and 12 months) 
post one session of WLM.  There were no significant results after one session.  After two 
sessions, there were only 11 observations, which was too few on which to conduct 
analysis.   
The key idea of the socio-economic model that framed this study is that the three 
levels (microsystem, mesosystem, and exosystem) all interact with each other.    The 
variables at the microsystem level that were statistically significant were weight loss, 
hypertension medication cessation, and food diary reporting.  The significant amount of 
percent body weight lost by participants found by this research could also be an effect of 
the mesosystem level.  At the mesosystem level, the weekly WLM group dynamics might 
have affected the percent weight lost, food diary compliance, and attendance, though this 
variable was not measured.  Also, if participants signed up with a co-worker or friend, 
this would be at the mesosystem level.  Group dynamics or a “buddy system” was not a 
measured variable, but could affect the results.  Future programming could include 
incentivizing signing up with an accountability partner or buddy.  The reduction in 
hypertension medications after two sessions of WLM affects the exosystem level in that 
stopping medications means fewer pharmaceutical claims to the health plan.  Because 
UK has a self-funded health plan, cost savings to the health plan would get passed on to 
the individual employee, affecting the microsystem again.  The fact that higher 
attendance and food diary reporting can affect weight loss demonstrates the interaction 
between all three levels in that better attendance (microsystem) might be a result of who 
is in the group or the supportive environment of the group (mesosystem).  Increased 
attendance (microsystem) could lead to increased weight loss for several or all of the 
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group (mesosystem) and medication cessation which would affect the health plan costs 
(exosystem).  
Limitations  
 One limitation of this study was the lack of measurements, both biometric and 
behavioral.  The biometric measurement of blood pressure, blood glucose/AIC, or blood 
cholesterol levels would provide a more precise determination of changes occurring in 
the participant rather than relying on measuring medication cessation only.  Behaviorally, 
the lack of records for food diaries and physical activity reports were two measures that 
were collected, but limited the study.  Food diaries were not mandatory.  Physical activity 
was only self-reported at enrollment of each session and not throughout. 
Another limitation was the advanced knowledge of pharmaceuticals needed to 
determine if participants were reducing their medications instead of stopping their 
medications.  Reduction in medication could be via dosage, method of delivery, how 
often it is taken, or the type of medication.  The scope of this study was to determine if 
participants ceased taking medications.  
Finally, having low numbers of participants who were on medications for diabetes 
and cholesterol limited the analysis.  This is especially true regarding longitudinal 
analysis or testing more than one 10-week session.   Fewer and fewer participants 
enrolled in subsequent sessions, lowering the total number available to test.   
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Chapter 5 
 
Summary, Conclusions, and Implications 
This chapter will summarize the study, present conclusions, and discuss 
implications for research and practice.  Though culture is unique to each company or 
organization, there are some ideas that apply to more general worksite wellness 
programs.   
Summary  
 The purpose of this study was to determine the effectiveness of the worksite 
wellness weight loss program called Weight Loss Matters (WLM) for employees at the 
University of Kentucky.  The three main objectives were to measure the effect of Weight 
Loss Matters on employees from June 2006 to December 2011 in the areas of (1) 
prescription claims for hypertension, diabetes, and dyslipidemia, (2) weight loss, and (3) 
food diary compliance.   
Records were collected from paper files of WLM and from the UK Health Plan 
claims database.  These were merged into a single database for a final sample of 591 
participants.  Descriptive statistics were computed for those who completed one, two, 
three, four, and five sessions. Most participants (all but 18) had a BMI in the overweight 
or obese categories with most (n = 452) between 25.78 and 40.17.  Chi Square, 
ANCOVA and multiple and logistic regression were used to test the 13 hypotheses. The 
results showed the more classes attended in a session, the greater the percent body weight 
lost, regardless of sex.  Also, results indicated that the more food diaries completed in a 
session, the greater the percent body weight lost.  Additional analysis indicated that after 
two sessions of WLM, a significant number of participants were likely to cease taking 
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their blood pressure medication, but no change was found for diabetes or cholesterol 
medication users.     
Conclusions   
1. There were no statistically significant results for cessation of any medications 
after one session of WLM in the whole sample.  
2. After completing two sessions of WLM, there were statistically significant 
changes in hypertension medication cessation at six and 12 months post-
WLM.   
3. The participants demonstrated a statistically significant weight loss after one 
session (10 weeks). Those who continued attendance (multiple sessions), 
continued to have weight losses.  For one session, attending four classes was 
statistically significantly associated with weight loss. 
4. There was a statistically significant positive association between food diary 
compliance and weight loss.  Both class attendance and completion of food 
diaries were the strongest predictors of weight loss.  
5. Having a goal of “doctor’s suggestion/medical reason” statistically 
significantly predicted weight loss for those who enrolled in one session, 
though only one person listed this as a goal.   
Overall, the Weight Loss Matters program at the University of Kentucky has 
achieved moderate gains for participants.  Gains were seen in weight loss and stopping 
hypertension medications after two sessions.  Direct measurements of blood pressure, 
blood glucose/A1C, and blood lipids might yield more positive results from the program.  
In addition, modifications in the program (see implications section) could also yield more 
effects.  
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Implications 
These results show value of the program on an individual level and a University-
wide level.  Weight loss and medication cessation are important to people.  As a result of 
participation in a wellness program, people might feel better, look better, have better 
health, have decreased medication costs, or decreased healthcare costs in general.  This is 
also of value on a greater scale.  Happier and healthier employees have better morale, less 
absenteeism, and less presenteeism.  Fewer medication claims against the health plan 
could cause the total cost of the health plan to the University to decrease.  Since Weight 
Loss Matters has achieved moderate gains for participants, it should be continued.  
Attempts to improve the program should be undertaken and data should be collected to 
determine if the changes are impactful.   
After two sessions (20 weeks) of completing WLM, participants were 
significantly more likely to cease taking their blood pressure medications.  What is not 
known is if the two sessions of WLM were back to back or had a time lapse.  Since 
changes were seen over time, the program facilitators might consider extending the 
sessions from 10 weeks (current length) to 12-15 weeks.  Since completion of one session 
was considered six or more classes and people averaged 5.6 classes, two completed 
sessions would mean approximately12 classes.  While some have perfect attendance and 
some only completed six classes, extending the program to 15 weeks would allow the 
participants more time to address and implement the recommended behaviors and still 
account for the average attendance of approximately half of the classes.  Another option 
would be to inform participants they are likely to achieve more weight loss and cease 
taking their medications if they attend more classes.  Knowledge alone can be a motivator 
for behavior change, but as already demonstrated in the Transtheoretical Model, there are 
85 
 
several constructs that can affect actions toward behavior change. According to the WHO 
(2003), there are five dimensions of adherence to both drugs and lifestyle modifications: 
social/economic factors, therapy-related factors, patient-related factors, condition-related 
factors, and health system/HCT-factors.  Though WLM cannot affect all of these 
dimensions, at least extending the program as an option can affect patient-related and 
social/economic factors.    Additionally, incentives or challenges for attendance might 
yield higher attendance and greater effects.   
 The WLM program should consider measuring blood pressure, blood 
glucose/AIC, and blood cholesterol levels prior to the program and after the program to 
more directly document possible reduction in these values that could lead to the stopping 
of medications.  Therefore, there is an opportunity for future research to examine other 
data that could indicate success in the program  
Because there was a significant relationship between food diaries completed and 
percent body weight lost; the program should consider incenting the use of food diaries 
instead of making it optional.  For some participants, simply knowing that more food 
diaries equal more weight lost might be incentive enough to complete them.  For others, 
added incentives for food diary completion could be a simple solution and added layer of 
support for weight loss.  The reason food diary completion was associated with increased 
weight loss might be because the food diaries or that self-monitoring makes the behavior 
more salient.  Food diaries are not just about self-monitoring, but also for reflection and 
insight about food choices.  Another option for increasing food diary compliance is the 
use of technology (i.e. a smart phone application), which is more readily available.  
 Physical activity was self-reported and not found to be a statistically significant 
predictor of weight loss, consistently.  Perhaps incorporating physical activity more 
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fundamentally into the program and following up after one session would underline the 
importance of physical activity to the participants. Once participants begin to lose weight, 
exercise habits might change.   
Because the goal of ‘doctor’s suggestion/medical condition’ was a significant 
predictor of weight loss, the program could consider strengthening the referral process 
between the WLM program and health care providers to gain more participants with this 
goal. The current (to the time) system in places involved a full time Health and Wellness 
staff person assigned to build relationships with the health care providers within the 
University clinics with the hope of receiving more referrals from providers to Health and 
Wellness professionals.  However, only participant has this goal listed and therefore these 
implications are speculative.  The implications for increasing provider referrals could 
lead to more weight loss for those who become enrolled, further reduction of 
medications, and greater cost savings across the individual level and University wide.   
No statistical significance was found for stopping diabetes or cholesterol 
medications after one or two sessions of WLM. This was likely due to the low number of 
participants who were taking these types of medications. Targeted marketing by WLM 
staff to those with diabetes or dyslipidemia could result in greater numbers enrolled; then 
more research could be completed.  Other reasons for no significant changes for these 
two conditions might also be the conditions themselves are related more to genetics when 
compared to hypertension and less affected by food choices and activity habits 
(behaviors).  Considering the goal of “doctor’s suggestion/medical reason” was a 
significant predictor of weight loss and there were no significant results for medication 
cessations for cholesterol or diabetes, perhaps focusing on educating older persons to get 
the appropriate checkups so the health care providers can then refer or suggest they lose 
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weight because of a medical reason, this could have a positive effect on increasing 
enrollment into the program.   
There was a larger number of participants on hypertension medications with only 
ten participants on multiple medications.  In a study by Nguyen, Varela, Sabio, Naim, 
Stamos, and Wilson (2006), for obese patients on multiple medications after bariatric 
surgery the participants reduced the number of medications they were taking from 2.4 to 
0.2.  This research is informative in showing a reduction of medications, but does not 
speak to which medications are stopped first.  After searching current literature, there is 
an apparent lack of research in finding which medications are stopped when 
comorbidities are present.   
Additionally, research to detect the time it takes for medications to be reduced or 
stopped is also lacking.  Though this current research demonstrated hypertension 
medication cessation after 20 weeks for completers versus non-completers, there seems to 
be mixed results in a research review.  Aldana et al. (2005) demonstrated an improvement 
in diabetes risk after six months of a Diabetes Prevention Program held within the 
worksite.  Fielding (1984) found hypertension improvements after one year.  Finkelstein, 
Linnan, Tate, and Leese (2009) found no medical cost savings at 12 months or the 
subsequent two years after losing 5% body weight in a worksite wellness weight loss 
program.  However, Trogdon, Finkelstein, Reyes, and Dietz were able to demonstrate a 
5% weight reduction resulted in a $90 per person savings in medical costs plus 
absenteeism at one year.  These varied results indicate a need for further research 
regarding the time it takes to reduce or stop medication after weight loss.   
This research has demonstrated positive effects for the employees at the 
University of Kentucky.  The research fits into the Strategic plan, as previously 
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mentioned.  It has potential to impact cost savings for the individual and also for the 
University, also as previously mentioned.  However, WLM could be used as a template 
for other health promotion programs targeting weight loss and its effects in other 
worksite wellness programs, but also in general.  Community groups, health departments, 
and civil organizations could use the WLM template to impact a greater number of 
people.  There are also possibilities for future research opportunities with the Health and 
Wellness program working in close proximity with the faculty of the Kinesiology and 
Health Promotion Department.  
More broadly, this research has not only demonstrated its efficacy for health 
promotion programming within worksite wellness programs, but could have greater 
impacts on health promotion policy.   The 1986 Ottawa Charter adopted by the WHO at 
the first Global Conference on Health Promotion put health promotion on the global 
radar.  The charter has been updated, changed, and globalized even mores since then.  
Specifically, in 2005, the 6th Annual Global Conference on Health Promotion which was 
held in Bangkok, laid out four key action areas: “to make the promotion of health central 
to the global development agenda, a core responsibility for all of government, a key focus 
of communities and civil society, and a requirement for good corporate practices” 
(http://www.who.int/healthpromotion/conferences/6gchp/bangkok_charter/en/).  This 
research fits into the fourth area of making health promotion a requirement for good 
corporate practice.  This includes promoting health and well-being to employees and their 
families.     
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Appendix A 
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Appendix B 
 
 
Name:_____________________  Meal Plan: __________ kcal at _______ activity level 
 
 
 
 
 
 
 
 
 
 
 
Session start wt. lbs. 
Session wt. loss goal
 
Dat
 
Weigh
 
Total 
 
Goal 
 
Met goal yes
  
Session start wt. lbs. 
Session wt. loss goal lbs. 
Date Weight Total loss 
Goal weight Met goal yes no 
Session start wt. lbs. 
Session wt. loss goal
 
Dat
 
Weigh
 
Total 
 
Goal 
 
Met goal yes
  
Session start wt. lbs. 
Session wt. loss goal lbs. 
Date Weight Total loss 
Goal weight Met goal yes no 
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Appendix C 
NAME: _______________________ 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Breakfast                              Date _________ 
  
  
Starch 
                
   
 
Fruit            
 
Veggie              
 
Meat                
 
Milk         
 
Fat              
 
Water                 
 
  
Lunch 
  
  
  
Dinner 
  
  
  
Breakfast  Date _________ 
  
  
  
Lunch 
  
  
  
Dinner 
  
 
 
 
Starch                    
 
Fruit            
 
Veggie              
 
Meat                
 
Milk         
 
Fat              
 
Water                 
 
 
DIRECTIONS: Write the date in the space provided (each 
box represents one day). On the left of each box, record 
what you eat each day. On the right of each box, check 
the boxes as you eat foods from each food group.  At the 
end of the day, you should have checked the number of 
boxes in each food group as indicated by your meal plan. 
 
 
MY MEAL PLAN: 
Starch   ____ exchanges Meat ____ exchanges 
Fruit  ____ exchanges  Milk  ____ exchanges 
Vegetable  ____ exchanges Fat  ____ exchanges 
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Appendix D 
Drug alt name uses explanation side effects Source 
Vytorin 
ezetimibe/si
mvastatin cholesterol 
blocks the 
absorption of 
cholesterol from 
food AND reduces 
cholesterol the body 
makes naturally 
loss of appetite, upper belly pain, 
dark urine, yellowing of skin or 
whites of eyes, feel tired/weak; 
headache, increased liver enzyme 
levels, muscle pain, upper 
respiratory infection, diarrhea; 
allergic reactions, joint pain, 
inflammation of pancreas, nausea, 
dizziness, tingling sensation, 
depression, gallstones, trouble 
sleeping, poor memory, 
confusion, ED, breathing 
problems/cough/SOB 
http://www.vytorin.com/ezetimibe_simvastatin/vyto
rin/consumer/about_vytorin/index.jsp?WT.mc_id=Y
03R1&utm_source=google&utm_medium=cpc&ut
m_term=vytorin&utm_campaign=Branded_2013&u
tm_content=swVnTtv9v|dc_pcrid_18912150850 
Simvastatin see above cholesterol     
Simvastatin Zocor cholesterol 
HMG-CoA 
reductase inhibitor 
(statin) 
Headache, nausea, vomiting, 
diarrhea, abdominal pain, muscle 
pain, abnormal liver tests; liver 
damage, muscle inflammation or 
breakdown; rhabdomyolysis. http://www.medicinenet.com/simvastatin/page2.htm 
Zocor see above cholesterol     
Crestor 
rosuvastatin 
calcium cholesterol 
blocks enzyme in 
liver causing liver to 
make less chol and 
increases uptake and 
breakdown by liver 
of chol already in 
blood 
muscle problems, liver problems, 
headache, muscle aches, 
abdominal pain, weakness, 
nausea, high blood sugar, 
memory loss/confusion 
http://www.crestor.com/c/about-crestor/crestor-side-
effects.aspx 
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Zetia ezetimibe  cholesterol 
works in digestive 
tract to block 
absorption of chol 
from food you eat 
diarrhea, joint pain, feeling  tired; 
muscle problems, allergic 
reactions, rash, joint pain, muscle 
pain, alterations in lab tests, liver 
problems, stomach pain, 
inflammation of pancreas, nausea, 
dizziness, tingling, depression, 
headache, gallstones, 
inflammation of gallbladder 
http://www.zetia.com/ezetimibe/zetia/consumer/abo
ut-zetia/faqs.jsp 
Pravastatin 
Sodium Prevachol cholesterol 
reversible inhibitor 
of the enzyme that 
catalyzes the 
conversion of 
HMG-CoA to 
mevalonate, early 
and rate limiting 
step in biosynthetic 
pathway for chol.  
Reduces VLDL and 
TG and increases 
HDL-C. 
cardio angina pectoris, rash, 
nausea/vomiting, diarrhea, 
flatulence; dyspepsia/heartburn, 
abdominal distension; fatigue, 
chest pain, influenza, muscle 
pain, myalgia, headache, 
dizziness, pharyngitis, upper 
respiratory infection, rhinitis, 
cough 
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=dcf45e4f-b46e-6fbb-b67a-2ff619ab1780 and 
http://www.drugs.com/pravastatin.html 
Atorvastatin 
Calcium Lipitor cholesterol 
Inhibitor of HMG-
CoA reductase.  
This enzyme 
catalyzes the 
conversion of 
HMG-CoA to 
mevalonate, an early 
and rate limiting 
step in cholesterol 
biosynthesis 
nasopharyngitis, arthralgia, 
diarrhea, pain in extremity, UTI, 
dyspepsia, nausea, 
musculoskeletal pain, muscle 
spasms, myalgia, insomnia, 
pharynogolaryngeal pain 
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=d385e07a-c16f-4aef-8e55-af95bd1c7526 
Lipitor see above cholesterol     
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Fenofibrate 
Antara, 
Fenoglide, 
Lipidil, 
Lipofen, 
TriCor, 
Triglide, 
Trilipix cholesterol 
antillipemic agents, 
speeds up natural 
processes that 
remove chol from 
body 
constipation, diarrhea, heartburn, 
pain in back/arm/legs, headache 
https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a601052.html 
Trilipix Fibricor cholesterol     
TriCor 
Fenoglide, 
Tricor, 
Lipofen, 
Antara, 
Triglide, 
Lofibra cholesterol     
Fenofibrate 
Micronized  cholesterol     
Gemfibrozil Lopid cholesterol 
class: fibrates, 
reduces the 
production of 
triglycerides in the 
liver 
stomach pain, heartburn, muscle 
pain/tenderness/weakness, blurred 
vision 
https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a686002.html 
GlyBURIDE-
Metformin Glucovance Diabetes 
glyburide/metformin 
hydrocholoride 
Lactic acidosis (can be fatal), 
muscle pain/weakness, numb or 
cold feeling in arms/legs, trouble 
breathing, stomach pain, nausea 
w/ vomiting, slow/uneven HR, 
dizziness, feeling weak/tired. http://www.rxlist.com/glucovance-drug.htm 
Janumet 
sitagliptin 
and 
metformin 
HCI Diabetes 
helps pancreas make 
more insulin, helps 
body more 
effectively use the 
insulin, and 
decreases excess 
sugar that your liver 
makes 
Lactic acidosis (can be 
fatal),pancreatitis (also fatal), 
kidney problems, stuffy/runny 
nose, sore throat, upper 
respiratory infection, diarrhea, 
nausea, vomiting, gas, upset 
stomach, indigestion, weakness, 
headache, low blood sugar 
http://www.janumetxr.com/sitagliptin_metformin_H
CL/janumetxr/consumer/what-is-
janumet/index.xhtml 
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Metformin 
Hydrochloride 
actoplus 
met, 
Actoplus 
Met XR, 
Avandamet, 
Fortamet, 
Glucophage, 
Glucophage 
XR, 
Glucovance, 
Glumetza, 
Janumet, 
Metaglip, 
Prandimet, 
Riomet Diabetes 
antihyperglycemic 
agent, lowers basal 
and postprandial 
plasma glucose.  
Decreases hepatic 
glucose production, 
decreases intestinal 
absorption of 
glucose, and 
improves insulin 
sensitivity by 
increasing 
peripheral glucose 
uptake and 
utilization.   
lactic acidosis, diarrhea, 
nausea/vomiting, flatulence, 
asthenia, indigestion, abdominal 
discomfort, headache 
http://www.fda.gov/ohrms/dockets/dailys/02/May02
/053102/800471e6.pdf and 
http://www.drugs.com/monograph/metformin-
hydrochloride.html 
Acarbose 
Prandase or 
Precose Diabetes 
Works by slowing 
the action of certain 
chemicals that break 
down food to release 
glucose into your 
blood.   
shakiness, 
dizziness/lightheadedness, 
sweating, nervousness/irritability, 
sudden changes in behavior or 
mood, headache, numbness or 
tingling around mouth, weakness, 
pale skin, hunger, clumsy or jerky 
movements 
https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a696015.html 
Actos pioglitazone Diabetes 
Thiazolidinedione 
that depends on 
presence of insulin 
for action.  
Decreases insulin 
resistance in 
periphery and liver, 
resulting in 
increased insulin 
dependent glucose 
disposal and 
decreased hepatic 
glucose output.   
low blood sugar, liver problems, 
bladder cancer, broken bones, 
macular edema, ovulation, cold-
like symptoms, headache, sinus 
infection, muscle pain, sore throat 
http://www.fda.gov/downloads/Drugs/DrugSafety/U
CM183833.pdf and 
http://www.drugs.com/pro/actos.html 
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Avandia 
rosiglitazone 
maleate Diabetes 
Increasing insulin 
sensitivity, improves 
glycemic control 
while reducing 
circulating insulin 
levels.  Improves 
sensitivity to insulin 
in muscle an adipose 
tissue and inhibits 
hepatic 
gluconeogenesis. 
heart failure, swelling, low blood 
sugar, fractures, weight gain, 
anemia, ovulation, liver problems 
http://www.fda.gov/downloads/Drugs/DrugSafety/P
ostmarketDrugSafetyInformationforPatientsandProv
iders/UCM143413.pdf 
Byetta Exenatide Diabetes 
Helps pancreas 
make more insulin 
more efficiently. 
low blood sugar, kidney 
problems, severe allergic 
reactions, nausea, vomiting, 
diarrhea, feeling jittery, dizziness, 
headache, acid stomach, 
constipation, weakness 
http://www.fda.gov/downloads/Drugs/DrugSafety/U
CM191084.pdf and 
http://www.drugs.com/byetta.html 
Glimepiride Amaryl Diabetes 
causes pancreas to 
produce insulin 
helps body use 
insulin efficiently 
dizziness, nausea, yellowing of 
skin or eyes, light colored stools, 
dark urine, pain in upper right 
stomach, unusual 
bleeding/bruising, diarrhea, fever, 
sore throat 
https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a696016.html 
GlipiZIDE Glucotrol Diabetes 
causes pancreas to 
produce insulin 
helps body use 
insulin efficiently 
diarrhea, gas, feeling jittery, 
dizziness, uncontrollable shaking 
of a part of the body, red or itchy 
skin, rash, hives, blisters, 
yellowing of skin or eyes, light 
colored stools, dark urine, pain in 
upper right stomach, unusual 
bleeding/bruising, diarrhea, fever, 
sore throat 
https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a684060.html 
GlipiZIDE 
Extended 
Release  Diabetes     
GlipiZIDE XL  Diabetes     
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GlyBURIDE 
Micronase, 
DiaBeta, 
Glynase, 
glibenclami
de Diabetes 
causes pancreas to 
produce insulin 
helps body use 
insulin efficiently 
nausea, upper abdominal fullness, 
heartburn, rash, yellowing of skin 
or eyes, light colored stools, dark 
urine, pain in upper right 
stomach, unusual 
bleeding/bruising, diarrhea, fever, 
sore throat 
https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a684058.html 
GlyBURIDE-
Metformin  Diabetes     
Humalog 
insulin 
lispro Diabetes 
regulation of 
glucose, Is a form of 
insulin  
hypoglycemia, renal impairment, 
hepatic impairment, allergy 
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=b34cd3ff-d0af-4852-b4ef-2a8b4a93aeae#s20 
Humalog 
Cartridge  Diabetes     
Humalog Pen  Diabetes     
Lantus 
insulin 
glargine Diabetes 
long acting human 
insulin analogues to 
improve glycemic 
control 
headache, flu like symptoms, 
dyspepsia, diarrhea, back pain, 
pharyngitis, lipodystrophy, 
lipohypertrophy, pallor, 
palpitation, tachycardia, local 
allergic reaction, hypokalemia, 
peripheral edema 
http://reference.medscape.com/drug/lantus-toujeo-
insulin-glargine-999003#4 
Lantus 
OptiClik 
Cartridge see above Diabetes     
Lantus 
Solostar Pen see above Diabetes     
Novolin R  Diabetes 
insulin-controls the 
storage and 
metabolism of 
carbohydrates, 
proteins, and fats 
skin rash, SOB, fast HR, 
sweating, drop in BP 
http://dailymed.nlm.nih.gov/dailymed/archives/fdaD
rugInfo.cfm?archiveid=10574 
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NovoLog  Diabetes insulin  
hypoglycemia, headache, injury 
accidental, nausea, diarrhea 
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=3a1e73a2-3009-40d0-876c-b4cb2be56fc5 
NovoLog 
FlexPen see above Diabetes     
NovoLog Mix 
70/30 FlexPen  Diabetes 
rapid acting and 
long acting insulin 
mix 
hypoglycemia, headache, flue like 
symptoms, dyspepsia, back pain, 
diarrhea, pharyngitis, rhinitis, 
skeletal pain, upper respiratory 
tract infection 
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=973a9333-fec7-46dd-8eb5-25738f06ee54 
Prandin repaglinide Diabetes 
lowers blood 
glucose by 
stimulating the 
release of insulin 
from pancreas 
hypoglycemia, respiratory 
infection, nausea, diarrhea, 
constipation, vomiting, dyspepsia, 
back pain, arthralgia, headache, 
paresthesia, chest pain, UTI, tooth 
disorder, allergy 
http://www.accessdata.fda.gov/drugsatfda_docs/labe
l/2009/020741s035lbl.pdf 
Hydrochloroth
iazide-
Lisinopril 
Prinzide or 
Zestoretic HTN 
Lisinopril is ace 
inhibitor, relaxes 
blood vessels.  
Hydrochlorothiazide 
is diuretic,  
blurred vision, body aches or 
pain, chills, confusion, cough, 
diarrhea, difficulty breathing, 
dizziness, faintness, 
lightheadedness, ear congestion, 
fever, headache, loss of voice, 
nasal congestion, nausea, runny 
nose, sneezing, sore throat, 
sweating, unusual tiredness or 
weakness, vomiting; acid/sour 
stomach, belching, 
burning/crawling/tingling, 
decreased libido, heartburn, 
inability to have or keep erection, 
indigestion, lack/loss of strength, 
loss of sexual performance, 
muscle cramps, rash, stomach 
discomfort/pain;  
http://www.mayoclinic.org/drugs-
supplements/lisinopril-and-hydrochlorothiazide-
oral-route/description/drg-20069073 
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Hydrochloroth
iazide-
Losartan  HTN     
Hydrochloroth
iazide-
Triamterene Maxide-25 HTN     
Hydrochloroth
iazide-
Valsartan  HTN     
Avalide/Avapr
o 
irbesartan, 
hydrochlorot
hiazide HTN see above see above 
http://www.fda.gov/Drugs/ResourcesForYou/Specia
lFeatures/ucm298226.htm 
Irbesartan  HTN see above    
Hydrochloroth
iazide  HTN see above    
Metoprolol 
Succinate ER Toprol HTN Beta blocker 
drowsiness, dizziness, tiredness, 
diarrhea, slow HR, decreased 
sexual ability, cold feelings in 
hands/feet; mood changes, SOB, 
sudden wt gain; rash,  
http://www.webmd.com/drugs/drug-8814-
Metoprolol+Succinate+Oral.aspx?drugid=8814 
Toprol XL see above HTN see above see above   
Clonidine 
Hydrochloride Clorpres HTN 
antihypertensive 
agent and diuretic 
dry mouth, increased thirst, 
drowsiness, feeling restless, 
nausea, vomiting, increased 
urination, muscle pain/weakness, 
fast HR, lightheaded, fainting, 
seizure, easy bruising/bleeding, 
red or purple spots on skin, 
confusion, hallucinations, 
urinating more or less than usual, 
SOB, swelling, rapid wt gain, 
numbness/tingly, nausea, stomach 
pain, low fever, loss of appetite, 
dark urine, clay colored stools, 
jaundice; dry mouth, loss of 
appetite, diarrhea, constipation, 
http://www.rxlist.com/clorpres-drug/patient-images-
side-effects.htm 
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upset stomach, dizziness, 
drowsiness, headache, feeling 
restless or nervous, sleep 
problems, nightmares or unusual 
dreams, breast swelling or 
tenderness, mild itching or skin 
rash, impotence or loss of interest 
in sex 
Catapres-TTS-
1 
clonidine, 
transdermal 
patch HTN 
stimulates alpha-
adrenoceptors in 
brain stem, resulting 
in reduced outflow 
from central nervous 
system and decrease 
in peripheral 
resistance, renal 
vascular resistance, 
HR, and BP 
dry mouth, drowsiness, fatigue, 
headache, lethargy and sedation, 
insomnia, dizziness, 
impotence/sexual dysfunction, 
dry throat, constipation, nausea, 
change in taste, and nervousness 
http://dailymed.nlm.nih.gov/dailymed/archives/fdaD
rugInfo.cfm?archiveid=13567 
Lisinopril 
Prinivil or 
Zestril HTN  
cough, dizziness, headache, 
excessive tiredness, nausea, 
diarrhea, weakness, sneezing, 
runny nose, decrease in sexual 
ability; swelling of 
face/throat/tongue/lips/eyes/hands
/feet, hoarseness, difficulty 
breathing/swallowing, fever, sore 
throat, chills, signs of infection, 
yellowing of skin or eyes, 
lightheadedness, fainting, chest 
pain   
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Diovan HCT 
valsartan 
and 
hydrocholrot
hiazide usp HTN 
valsartan is 
angiotensin II 
receptor blocker and 
hydrochlorothiazide 
is diuretic 
Allergic reaction, breakdown of 
skeletal muscle resulting in 
kidney failure, eye pain/vision 
problems, light headed or 
fainting, swelling rapid weight 
gain, fast or pounding HR, 
urinating less than usual, 
jaundice, dry mouth/increased 
thirst, drowsiness, restless feeling, 
confusion 
http://www.rxlist.com/diovan-hct-drug/patient-
images-side-effects.htm 
Benicar 
Olmesartan, 
hydrochlorot
hiazide, 
Atacand, 
Avapro, 
Cozaar, 
Diovan, 
Micardis, 
Teveten HTN 
angiotensin II 
receptor blocker,  see above 
http://www.fda.gov/Drugs/DrugSafety/PostmarketD
rugSafetyInformationforPatientsandProviders/ucm2
15245.htm 
Nadolol Corgard HTN 
beta-adrenergic 
receptor blocker 
Dizziness or lightheadedness, 
excessive tiredness, SOB, 
swelling in hands, feet, ankles, 
lower legs; unusual wt gain, 
fainting,  
https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a682666.html and 
http://labeling.pfizer.com/ShowLabeling.aspx?id=70
8 
Metoprolol 
Tartrate Lopressor HTN 
beta-selective 
(cardioselective) 
adrenergic receptor 
blocker.   
tiredness/dizziness, sob, 
bradycardia, cold extremities, 
arterial insufficiency, palpitations, 
CHF, peripheral edema, 
hypotension, wheezing, diarrhea, 
nausea, dry mouth , gastric pain, 
constipation. Flatulence, 
heartburn, vomiting, pruritus/rash, 
peyronies disease, pain. blurred 
vision, tinnitus 
http://www.drugs.com/cdi/metoprolol-tartrate.html 
and 
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=011ee828-5c2a-49b9-bf8e-07f5eb5fc635 
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Spironolactone Aldactone HTN 
potassium-sparking 
diuretic that 
prevents the body 
from absorbing too 
much salt and keeps 
potassium levels 
from getting too low 
vomiting, diarrhea, stomach 
pain/cramps, dry mouth, thirst, 
dizziness, unsteadiness, headache, 
enlarge/painful breasts, irregular 
menstrual periods, vaginal 
bleeding in post men, difficulty 
maintaining or achieving erection, 
deepening of voice, increased hair 
growth on body parts, drowsiness, 
tiredness, restlessness 
https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a682627.html and 
http://www.drugs.com/spironolactone.html 
Amlodipine 
Besylate 
Norvasc, 
Azor HTN 
besylate salt of 
amlodipine, a long 
acting calcium 
channel blocker, 
inhibits 
transmembrane 
influx of calcium 
ions into vascular 
smooth muscle and 
cardiac muscle.    
Amlodipine is 
peripheral arterial 
vasodilator causing 
reduction in 
peripheral vascular 
resistance and 
reduction in bp.   
edema, dizziness, flushing, 
palpitation 
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=2bac4ec4-9542-4927-8121-a7cd1858075b and 
http://www.webmd.com/drugs/2/drug-
5891/amlodipine-oral/details 
Afeditab CR 
nifedipine, 
Adalat CC, 
Afeditab 
CR, 
Nifediac 
CC, 
Nifedical 
XL, 
Procardia, HTN 
Calcium channel 
blocker, relaxes 
cardiac muscle and 
blood vessels 
worsening angina, light headed, 
pounding heartbeat, chest pain, 
swelling in ankles or feet, 
stomach pain, dizziness, 
weakness, headache, mood 
changes, heartburn, nausea, 
tremors, muscle cramps, cough, 
wheezing, sore throat or stuffy 
nose http://www.drugs.com/mtm/afeditab-cr.html 
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Procardia 
XL 
Nifediac CC see above HTN     
Nifedical XL see above HTN     
Nifedipine ER see above HTN     
Nisoldipine see above HTN     
Sular nisoldipine HTN     
Amlodipine 
Besylate-
Benazepril 
Hydrochloride Lotrel HTN 
calcium channel 
blocker and ACE 
inhibitor, relaxes 
blood vessels to help 
flow 
dizziness, cough, swelling 
hands/ankles/feet, fainting, 
irregular heartbeat, high 
potassium, weakness, sore throat, 
liver problems, chest pain or heart 
attack,  
http://www.fda.gov/Safety/MedWatch/SafetyInform
ation/ucm262165.htm and 
http://www.webmd.com/drugs/2/drug-
11524/amlodipine-benazepril-oral/details#side-
effects 
Lotensin 
benazepril 
hydrochlorid
e HTN 
non-sulfhydryl 
angiotensin-
converting enzyme 
inhibitor 
headache, dizziness, somnolence, 
postural dizziness 
http://www.accessdata.fda.gov/drugsatfda_docs/labe
l/2012/019851s042lbl.pdf 
Atenolol Tenormin HTN Beta blocker,  
dizziness, lightheadedness, 
tiredness, drowsiness, depression, 
nausea, diarrhea, SOB, swelling 
of hands or feet, weight gain, 
fainting 
https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a684031.html 
Bisoprolol 
Fumarate  HTN 
Beta blocker-relaxes 
blood vessels and 
slows heart rate to 
improve and 
decrease BP. 
excessive tiredness, vomiting, 
diarrhea, muscle aches, runny 
nose; SOB, swelling of hand/feet, 
unusual weight gain, fainting,  
https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a693024.html 
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Bystolic nebivolol HTN 
beta blocker, relaxes 
blood vessels 
headache, fatigue, dizziness, 
diarrhea, nausea, insomnia, chest 
pain, bradycardia, SOB, rash, 
peripheral edema http://www.bystolic.com/ 
Cartia XT 
diltiazem, 
Cardizem HTN 
calcium channel 
blocker, relaxes 
blood vessels so 
blood flows more 
easily, lowers HR 
dizziness, lightheadedness, 
weakness, nausea, flushing, 
constipation, headache 
https://healthy.kaiserpermanente.org/health/care/con
sumer/health-wellness/drugs-and-natural-
medicines/drug-encyclopedia/medicine-
information/!ut/p/a1/hc_BTsJAEAbgp-
FIZ9qFdvG2gOK2ArU2UvdiSllbkmW3KQsNPr0U
8WCMOreZfPMnPwjIQOj8uC1zuzU6V90u_NcU-
XI8dhmiy4fI45AuppR6OCGwghBEqcz6gl8qa-
ubHvZw0xxKqYtTvzaNVdL2EIQyRa4kZFL3D_t_
dXfjU8i8URBQ_MYLo63UtpF6IxvZ_MxejUG02fu
mYt0f02tCSxCNfOu4U5m9haxtW6c0plTSKczuXE
T83RWv4C58-
gTLwYgin0_uJ3wRIc6CK4gZcjrHoYuM-
Mj9lETBfOHibHAFSPjjJWEW-
3i2URo9jyKC6H2BX4Yh1Dt6Iur4IJO1n9wm7AM
6_jt-/dl5/d5/L2dBISEvZ0FBIS9nQSEh/ 
Diltiazem 
Hydrochloride  HTN 
calcium ion cellular 
influx inhibitor 
(slow channel 
lower limb edema, sinus 
congestion, rash NOS 
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=813eb1bb-1475-4958-821d-e97c5abb7462 
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blocker or calcium 
antagonist) 
Carvedilol Coreg HTN 
beta blocker, relaxes 
blood vessels 
extreme thirst, frequent urination, 
extreme hunger, weakness, 
blurred vision; tiredness, 
weakness, lightheadedness, 
dizziness, headache, diarrhea, 
nausea, vomiting, vision changes, 
joint pain, difficulty falling or 
staying asleep, cough, dry eyes, 
numbness, burning, or tingling in 
the arms or legs 
https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a697042.html 
Chlorthalidone 
Hygroton, 
Thalitone HTN 
water pill-causes the 
kidneys to get rid of 
unneeded water and 
salt 
muscle weakness, dizziness, 
cramps, thirst, stomach pain, 
upset stomach, vomiting, 
diarrhea, loss of appetite, 
headache, hair loss 
https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a682342.html 
Cozaar 
losartan 
potassium HTN 
Blocks the 
vasoconstrictor and 
aldosterone-
secreting effects of 
angiotensin II by 
selectively blocking 
the binding of 
angiotensin II to the 
AT receptor found 
in many tissues. 
abdominal or stomach pain, 
anxiety, bladder pain, bloody or 
cloudy urine, blurred vision, 
chills, cold sweats, coma, 
consution, cool pale skin, 
depression, difficult breathing, 
difficulty burning or painful 
urination, dizziness, fast 
heartbeat, frequent urge to 
urinate, headache, increased 
hunger, irregular heartbeat, lower 
back pain, nausea/vomiting, 
nightmares, numbness or tingling 
in hands feet or lips, pale skin, 
seizures, shakiness, SOB, slurred 
speech, trouble breathing w/ 
exertion, unusual bleeding or 
bruising, unusual 
 and 
https://www.merck.com/product/usa/pi_circulars/c/c
ozaar/cozaar_pi.pdf 
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tiredness/weakness, 
weakness/heaviness of legs 
Doxazosin 
Mesylate  HTN 
Selective inhibitor 
of alpha 1 subtype 
of adrenergic 
receptors.  Results 
in systemic vascular 
resistance. 
dizziness, fatigue, swelling of 
feet, SOB 
http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugX
sl.cfm?setid=345478a6-8389-4229-92b3-
6e40da7b06fd 
Enalapril 
Maleate  HTN 
Maleate salt of 
enalapril, the ethyl 
ester of a long 
acting angiotensin 
converting enzyme 
inhibitor, 
enalaprilat.  
Enalapril, after 
hydrolysis to 
enalaprilat, inhibits 
angiotensin-
converting enzyme 
(ACE) . 
fatigue, orthostatic effects, 
asthenia, diarrhea, nausea, 
headache, dizziness, cough, rash 
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=e31289f1-4b59-418a-a893-c748ce073f6c 
Felodipine 
Plendil, 
Lexxel (a 
combination 
drug) HTN 
calcium channel 
blocker, relaxes 
blood vessels so 
blood flows more 
easily, lowers HR 
headache, flushing, dizziness or 
lightheadedness, weakness, fast 
heartbeat, heartburn, constipation, 
enlargement of gum tissue around 
teeth 
https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a692016.html 
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Fosinopril 
Sodium Monopril HTN 
hydrolyzed by 
esterase to the 
pharmacologically 
active from, 
fosinoprilat, a 
specific competitive 
inhibitor of 
angiotensin 
converting enzyme 
(ACE) 
cough, dizziness, nausea, 
vomiting, headache, diarrhea, 
fatigue, sexual dysfunction 
http://dailymed.nlm.nih.gov/dailymed/archives/fdaD
rugInfo.cfm?archiveid=4617 
Guanfacine 
Hydrochloride 
Intuniv, 
Tenex HTN 
alpha2A-
adreneergic receipt 
agonists-decreases 
HR and relaxes 
blood vessels to 
blood can flow more 
easily 
dry mouth, tiredness, weakness, 
headache, irritability, decreased 
sexual ability, decreased appetite, 
stomach pain, nausea, vomiting, 
constipation, fainting, blurred 
vision, rash, slow HR 
https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a601059.html 
Hyzaar 
Losartan 
potassium 
and 
hydrochlorot
hiazide HTN 
angiotensin II 
receptor antagonist 
and a diuretic 
abdominal pain, edema/swelling, 
palpitation, dizziness, cough, 
sinusitis, URI, rash 
https://www.merck.com/product/usa/pi_circulars/h/h
yzaar/hyzaar_pi.pdf 
Indapamide Lozol HTN 
water pill-causes the 
kidneys to get rid of 
unneeded water and 
salt 
muscle cramps, drowsiness, 
confusion, thirst, upset stomach, 
vomiting, stomach cramps, 
decreased sexual ability, blurred 
vision 
https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a684062.html 
Labetalol 
Hydrochloride  HTN 
adrenergic receptor 
blocking agent 
postural hypotension, increased 
sweating, flushing 
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=17bb21ce-9bb1-4603-b168-abea7fc85d17 
Minoxidil 
Loniten, 
Rogaine, 
Renewal HTN 
vasodilator-relaxes 
blood vessels so 
blood can flow more 
easily 
increase in size or darkness of 
fine body hair, breast tenderness, 
headache, nausea, vomiting; rash, 
fast HR, swollen ankles/feet, 
unexplained weight gain, 
https://www.nlm.nih.gov/medlineplus/druginfo/med
s/a682608.html 
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difficulty breathing, dizziness, 
fainting 
Propranolol 
Hydrochloride  HTN 
synthetic beta-
adrenergic receptor 
blocker 
nausea, vomiting, epigastric 
distress, abdominal cramping, 
diarrhea, constipation, mesenteric 
arterial thrombosis, ischemic 
colitis, bronchospasm, Systemic 
lupus erythematosus, dry eyes, 
toxic epidermal necrolysis, 
urticaria, skin issues 
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=46942e6e-73bb-4687-853a-e3ec2734cc70 
Quinapril 
Hydrochloride 
accupril, 
accuprin, 
acequin, 
korec HTN 
salt form of 
quinapril, a prodrug 
and non-sulfhydryl 
angiotensin 
converting enzyme 
(ACE) inhibitor 
with 
antihypertensive 
activity-leads to 
vasodilation 
dizziness, lightheadedness, 
tiredness, cough, nausea, 
vomiting, fainting, muscle 
weakness, slow/irregular HR, 
change in amount of urine 
(http://www.webmd.com/drugs/2/
drug-6254/quinapril-oral/details#) 
http://pubchem.ncbi.nlm.nih.gov/compound/Accupri
l#section=Top 
Sotalol 
Hydrochloride  HTN 
antiarrhythmic drug 
with beta-
adrenoceptor 
blocker and cardiac 
action potential 
duration 
prolongation 
properties 
infection, fever, localized pain, 
cardiovascular symptoms, 
nervous system symptoms, 
digestive, respiratory, urogenital, 
metabolic, musculoskeletal, skin 
rash, bleeding, visual problems 
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=576905b7-6e6d-4aa0-b690-24be26e70cd2 
Verapamil 
Hydrochloride  HTN 
calcium ion influx 
inhibitor (slow 
channel blocker) 
modulates the influx 
of ionic calcium 
across the cell 
membrane of 
constipation, headache, dizziness, 
lethargy, dyspepsia, rash, ankle 
edema, sleep disturbance, myalgia 
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=3bee2d26-138c-4641-a217-a38d3d657461 
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arterial smooth 
muscle and 
conductile and 
contractile 
myocardial cells 
Verapamil 
Hydrochloride 
SR see above HTN     
Tamsulosin 
Hydrochloride Flomax 
not for use 
in HTN 
alpha 1 
adrenoceptor 
blocking agent-
selective for 
prostrate 
headache, infection, asthenia, 
back pain, chest pain, nervous 
system symptoms, respiratory, 
digestive, urogenital symptoms, 
blurred vision 
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=d302b0fb-4f03-4106-b484-1e811f62c356 
Flomax 
tamsulosin 
hydrochlorid
e 
Not 
indicated 
for HTN 
alpha adrenoceptor 
antagonist 
fainting, dizziness, 
lightheadedness, rash, itching, 
hives, runny nose, decreased 
semen 
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?
setid=c00d5f7b-dad7-4479-aae2-fea7c0db40ed 
Norvasc see above      
Lotrel see above      
Tiazac diltiazem  see above    
Diltzac 
diltiazem 
hydrochlorid
e      
Losartan 
Potassium see above      
     
Each of these contains 100 units 
of insulin as part per mL: 10 mL 
vials, 3 mL Pen Fill cartridges, 
3mL NovoLog FlexPen, 3 mL 
NovoLog FlexTouch   
Propranolol 
Hydrochloride 
LA see above   long acting        
 
108 
 
References 
Albu, J. B., Heilbronn, L. K., Kelley, D. E., Smith, S. R., Azuma, K., Berk, E. S., Pi- 
 Sunyer, X. …Ravnssin, E. (2010). Metabolic changes following a 1-year diet and  
 exercise intervention in patients with type 2 diabetes. Diabetes, 59, 627-633. 
American Heart Association. (2009). Position statement on effective worksite wellness  
programs. Retrieved from 
http://www.americanheart.org/presenter.jhtml?identifier=3065713. 
Appel, L. J., Moore, T. J., Obarzanek, E., Vollmer, W. M., Svetkey, L. P., Sacks, F. M  
...Karanja, N. (1997). A clinical trial of the effects of dietary patterns on blood 
pressure. The New England Journal of Medicine, 336(16), 1117-1124. 
Appel, L. J., Champagne, C. M., Harsha, D. W., Cooper, L. S., Obarzanek, E., Elmer, P.  
J. … (2003). Effects of comprehensive lifestyle medication on blood pressure 
control: Main results of the PREMIER clinical trial. Journal of the American 
Medical Association, 289 (16), 2083-2093. 
Astrup, S. J., McGovern, P. M., & Kochevar, L. K. (1992).  The Relationship between  
 
 wellness participation and health care benefit utilization. Benefits Quarterly (2nd  
 
 qtr), 41-54. 
 
Aucott, L. S. (2008). Symposium on ‘diet and diabetes’: Influences of weight loss on  
long-term diabetes outcomes. Proceedings of the Nutrition Society, 67, 54-59. doi: 
10.1017/S0029665108006022 
Avenell, A., Broom, J., Brown, T. J., Poobalan, A. Aucott, L., Stearns, S. C., … Grant,  
A.M. (2004). Systematic review of the long-term effects and economic 
consequences of treatments for obesity and implications for health improvement. 
Health Technology Assessment, 8(21), 1-458. 
109 
 
 
Avenell, A., Brown, T. J., McGee, M. A., Campbell, M. K., Grant, A. M., Broom, J. ...  
Smith, W.C.S. (2004). What interventions should we add to weight reducing diets 
in adults with obesity? A systematic review of randomized controlled trials of 
adding drug therapy, exercise, behavior therapy or combinations of these 
interventions. Journal of Human Nutrition and Dietics, 17, 293-316.  
Baranowski, T., Cullen, K. W., Nicklas, T., Thompson, D., & Baranowski, J. (2003). Are  
current health behavioral change models helpful in guiding prevention of weight 
gain efforts?  Obesity Research, 11, 23s-43s.  
Baumgartner, T. A., & Hensley, L. D. (2006). Conducting & reading research in health 
 & human performance (4th ed.). Boston: McGraw Hill.   
Behavioral Risk Factor Survey and Surveillance. (2009). Survey data and documentation.  
 [Data file and code book]. Retrieved from http://apps.nccd.cdc.gov/BRFSS/. 
Blumenthal, J. A., Sherwood, A., Gullette, E. C., Georgiades, A., Damon, T. (2002).  
Biobehavioral approaches to the treatment of essential hypertension. Journal of 
Consulting and Clinical Psychology, 70(3), 569-589. doi: 10.1037/0022-
006x.70.3.569  
Burke, L.E., Wang, J., Sevick, M.A. (2011). Self-monitoring in weight loss: A  
Systematic review of the literature. Journal of American Dietetic Association, 
111(1), 92-102. Doi: 10.1016/j.jada.2010.10.008 
Carls, G. S., Goetzel, R. Z., Henke, R. M., Bruno, J., Isaac, F., & McHugh, J. (2011). The  
Impact of weight gain or loss on health care costs for employees at the Johnson & 
Johnson family of companies. Journal of Occupational and Environmental 
Medicine, 53(1), 8-16. doi 10.1097/JOM.0b013e31820451fd 
Centers for Disease Control and Prevention. (2009). Retrieved from  
110 
 
http://www.cdc.gov/nchs/fastats/lcod.htm October 2012. 
Delahanty, L. M. (2002). Evidence-based trends for achieving weight loss and increased  
physical activity: Applications for diabetes prevention and treatment. Diabetes 
Spectrum, 15(3), 183-189. 
Di Noia, J., & Prochaska, J. O. (2010). Dietary stages of change and decisional balance:  
 A meta-analytic review. American Journal of Health Behavior, 34(5), 618-632.  
Dixon, J.B., Laurie, C.P., Anderson, M.L., Hayden, M.J., Dixon, M.E., O’Brian, P.E. 
(2009). Motivation, readiness to change, and weight loss following adjustable 
gastric band surgery. Obesity, 17, 698-705. doi:10.1038/oby.2008.609 
Eakin, E. G, Reeves, M. M., Marshall, A. L., Dunstan, D. W., Graves, N., Healy, G. 
N....Wilkie, K. (2010). Living well with diabetes: A randomized controlled trial 
of a telephone-delivered intervention for maintenance of weight loss, physical 
activity and glycemic control in adults with type 2 diabetes. Public Health, 10, 
452-466. 
Elhayany, A., Lustman, A., Abel, R., Attal-Singer, J., & Vinker, S. (2010).  A low  
carbohydrate Mediterranean diet improves cardiovascular risk factors and 
diabetes control among overweight patients with type 2 diabetes mellitus: a 1-year 
prospective randomized intervention study.  Diabetes, Obesity, and Metabolism, 
12, 204-209. 
Field, A. & Miles, J. (2010). Discovering Statistics Using SAS. Thousand Oaks, 
 California: Sage Publications. 
Finkelstein, E. A., Linnan, L. A., Tate, D. F., & Leese, P. J. (2009). A Longitudinal study  
111 
 
on the relationship between weight loss, medical expenditures, and absenteeism 
among overweight employees in the WAY to health study. Journal of 
Occupational and Environmental Medicine, 51(12), 1367-1373 
Fujioka, K. (2010). Benefits of moderate weight loss in patients with type 2 diabetes.  
 Diabetes, Obesity and Metabolism, 12, 186-194. 
Funk, K. L., Elmer, P. J., Stevens, V. J., Harsha, D. W., Craddick, S. R., Lin, P. H. ...  
 Appel, L.J. (2008). PREMIER-A trial of lifestyle interventions for blood pressure 
 control: intervention design and rationale. Health Promotion Practice, 9(3), 271- 
280. doi:10.1177/1524839906289035.  
Glanz, K., Rimer, B. K., & Viswanath, K. (Ed.). (2008). Health behavior and health  
 education: Theory, research, and practice. (4th ed.). San Francisco: Jossey-Bass. 
Goldgruber, J. & Ahrens, D. (2010). Effectiveness of workplace health promotion and  
 primary prevention interventions: a review. Journal of Public Health, 18, 75-88.  
 doi: 10.1007/s10389-009-0282-5 
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. 
 A., …Costa, F. (2006). Diagnosis and management of the metabolic syndrome:  
An American Heart Association/National Heart, Blood, and Lung Institute  
scientific statement. Current Opinion in Cardiology, 21(1), 1-6. 
Gustafson, A., Khavjou, O., Stearns, S. C., Keyserling, T. C., Gizlice, Z., Lindsley, S.... 
Samuel-Hodge, C.D. (2009). Cost effectiveness of a behavioral weight loss 
intervention for low-income women: The weight-wise program. Preventative 
Medicine, 49, 390-395. doi:10.1016/j.ypmed.2009.09.007 
Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delhanty, L.,  
…Wylie-Rosett, J. (2006). Effect of weight loss with lifestyle intervention on risk 
of diabetes. Diabetes Care, 29, 2102-2107. 
Harman, N. L., Leeds, A. R., Griffin, B. A. (2008). Increased dietary cholesterol does not  
112 
 
increase plasma low density lipoprotein when accompanied by an energy-
restricted diet and weight loss. European Journal of Nutrition, 47, 287-293. doi: 
10.1007/s00394-008-0730-y 
Hernandez, T. L., Sutherland, J. P., Wolfe, P., Allian-Sauer, M., Capell, W. H., Talley, N. 
D., …Eckel, R.H. (2010). Lack of suppression of circulating free fatty acids and 
hypercholesterolemia during weight loss on a high-fat, low carbohydrate diet. 
American Journal of Clinical Nutrition, 91, 578.585.   
Horton, E. S., Silberman, C., Davis, K. L., Berria, R. (2010). Weight loss, glycemic  
control, and changes in cardiovascular biomarkers in patients with type 2 diabetes  
receiving incretin therapies or insulin in a large cohort database. Diabetes Care, 
33(8), 1759-1765. 
Horvath, K., Jeitler, K., Siering, U., Soz, D., Stich, A. K., Soz-Pad, D., Skipka, G., 
...Siebenhofer, A. (2008). Long-term effects of weight-reducing interventions in 
hypertensive patients. Archives of Internal Medicine, 168(6), 571-580. 
Hughes, M. C., Girolami, T. M., Cheadle, A. D., Harris, J. R., & Patrick, D. L. (2007). A  
Lifestyle-based weight management program delivered to employees: 
Examination of health and economic outcomes. Journal of Occupational and 
Environmental Medicine, 49(11), 1212-1217. 
Johnson, S. S., Driskell, M. M., Johnson, J. L., Prochaska, J. M., Zwick, W., & 
Prochaska, J. O. (2006). Efficacy of a transtheoretical model-based expert system 
for antihypertensive adherence. Disease Management, 9(5), 291-301. 
Johnson, S. S., Paiva, A. L., Cummins, C. O., Johnson, J. L., Dyment, S. J., Wright, J. A.,  
113 
 
... Webber, L.S. (2008). Transtheoretical model-based multiple behavior 
interventions for weight management: Effectiveness on a population basis. 
Preventative Medicine, 46, 238-246. doi: 10.1016/j.ypmed.2007.09.010. 
Karlsen, T., Sohagen, M., & Hjelmesaeth, J. (2013). Predictors of weight loss after an  
 intensive lifestyle intervention program in obese patients: A 1-year prospective 
 cohort study. Health and Quality of Life Outcomes, 11, 165.  
Kempf, K., Kruse, J. & Martin, S. (2010). ROSSO-in-praxi: A Self-monitoring of blood  
 glucose-structured 12-week lifestyle intervention significantly improves  
 glucometabolic control of patients with type 2 diabetes mellitus. Diabetes  
 Technology & Therapeutics, 12(7),  547-553. doi: 10.1089/dia.2010.0008 
Layman, D. K., Evans, E. M., Erickson, D., Seyler, J., Weber, J., Bagshaw, D., …Kris- 
 Etherton, P. (2009). A moderate-protein diet produces sustained weight loss and  
 long-term changes in body composition and blood lipids in obese adults. The  
 Journal of Nutrition, 139, 514-521. doi: 10.3945/jn.108.099440. 
Logue, E. E., Jarjoura, D. G., Sutton, K. S., Smucker, W. D., Baughman, K. R., &  
 Capers, C. F. (2004). Longitudinal relationships between elapsed time in the  
 action stages of change and weight loss. Obesity Research, 12(9), 1499-1508.  
Lynch, W. D., (2002). What is a healthy employee worth? Absolute Advantage, 16-19. 
Matsuo, T., Kato, Y., Murotake, Y., Kim, M. K., Unno, H., & Tanaka, K. (2010). An  
increase in high-density lipoprotein cholesterol after weight loss intervention is 
associated with long-term maintenance of reduced visceral abdominal fat. 
International Journal of Obesity, 34, 1742-1751. 
McKenzie, J. F, Neiger, B. L., Smeltzer, J. L. (2005). Planning, implementing &  
evaluating health promotion programs: A primer (4th ed.). San Francisco: Pearson 
Benjamin Cummings. 
114 
 
McLeroy, K. R, Bibeau, D.,  Steckler, A., & Glanz, K. (1988).  An Ecological 
perspective on health promotion programs, Health Education and Behavior, 15, 
351.  doi:10.1177/109019818801500401 
Meckling, K. A. & Sherfey, R. (2007). A randomized trial of a hypercaloric high-protein  
diet, with and without exercise, on weight loss, fitness, and markers of the 
Metabolic Syndrome in overweight and obese women. Applied Physiology and 
Nutritional Metabolism, 32, 743-752. doi: 10.1139/H07-059. 
Mokdad, A.H., Ford, E.S., Bowman, B.A., Nelson, D.E., Engelgau, M.M., Vinicor, F.,  
…Marks, J.S. (2000). Diabetes trends in the US: 1990-1998. Diabetes Care, 23, 
1278-1283. 
Miller, E. R., Erlinger, T. P., Young, D. R. Jehn, M., Charleston, J., Rhodes, D., …Appel,  
L.J. (2002). Results of the diets, exercise, and weight loss intervention trial 
(DEW-IT). Hypertension: Journal of the American Heart Association, 40, 612-
618. doi: 10.1161/01.HYP.0000037217.96002.8E 
National Prevention, Health Promotion and Public Health Council. (2011). National  
Prevention Strategy: America’s plan for better health and wellness. Retrieved 
from http://www.Healthcare.gov 
O’Conell, D. & Velicer, W. F. (1988). A decisional balance measure and the stages of  
change model for weight loss. The International Journal of the Addictions, 23(7), 
729-750.   
Poobalan, A., Aucott, L., Smith, S., Avenell, A., Jung, R., Broom, J., Grant, A.M. (2004). 
Effects of weight loss in overweight/obese individuals and long-term lipid 
outcomes-a systematic review. The International Association for the Study of 
Obesity: Obesity reviews, 5, 43-50.  
115 
 
Renaud, L., Kishchuk, N., Juneau, M., Nigam, A., Tetreault, K., & Leblanc, M. C. (2008,  
 Jan-Feb). Implementation and outcomes of a comprehensive worksite health  
 promotion program. Canadian Journal of Public Health, 73-77. 
Samuel-Hodge, C. D,  Johnston,  L.F ., Gizlice, Z., Garcia, B.A., Lindsley, S.C.,  
Bramble, K.P., Hardy, T.E., …Keyserling, T.C. (2009). Randomized trial of a 
behaviors weight loss intervention for low-income women: The weight wise 
program. Obesity, 17, 1891-1899. Doi: 10.1038/oby.2009.128.  
Santosa, S., Demonty, I., Lichtenstein, A. H., & Jones, P. J. H. (2007). Cholesterol  
metabolism and body composition in women: the effects of moderate weight loss. 
International Journal of Obesity, 31, 933-941. 
Thompson, S. E., Smith, B. A., & Bybee, R. F. (2005). Factors influencing participation  
in worksite wellness programs among minority and underserved populations. 
Family Community Health, 28(3), 267-273. 
Torres, S. J. & Nowson, C.A. (2007). Effect of a weight-loss program on mental stress- 
induced cardiovascular responses and recover. Nutrition, 23, 521-528. doi: 
10.1016/j.nut.2007.04.016 
U. S. Department of Health and Human Services. Centers for Disease Control and  
 Prevention. (2010). High cholesterol: Understand your risks. Retrieved from  
http://www.cdc.gov/cholesterol/index.htm. 
van Dongen J. M., Proper, K. I., van Wier, M. F., van der Beek, A. J., P. M. Bongers, P. 
M., van Mechelen, W., & van Tulder, M. W. (2011). Systematic review on the 
financial return of worksite health promotion programmes aimed at improving 
nutrition and/or increasing physical activity. Obesity Management, 12, 1031-
1049. doi: 10.1111/j.1467-789X.2011.00925.x 
Wang, F., McDonald, T., Bender, J., Reffitt, B., Miller, A., & Eddington, D. (2006).  
116 
 
Association of healthcare costs with per unit body mass index increase. Journal of 
Occupational and Environmental Medicine, 48(7), 668-674. doi: 
10.1097/01.jom.0000225045.77734.f4 
World Health Organization, Global strategy on diet, physical activity, and health. (2011).  
 Retrieved from http://www.who.int/dietphysicalactivity/strategy/en/ 
http://www.uky.edu/Provost/strategic_planning/plan.htm, retrieved July 23, 2012. 
https://www.cdc.gov/brfss/questionnaires/pdf-ques/2011brfss.pdf, retrieved December 
21, 2016. 
http://www.uaex.edu/publications/pdf/fshed-86.pdf, retrieved January 12, 2017.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
117 
 
Carrie Davidson 
Place of birth: Carbondale, Illinois 
Education 
2004 Masters of Divinity, Gardner-Webb University, Boiling Springs, NC 
2001 Bachelor of Science, University of Southern Mississippi, Hattiesburg, MS 
 Major: Human Performance and Recreation, Emphasis: Exercise Physiology  
Professional Experience 
University of Kentucky-Wellness Coordinator, October 2006-June 2015.  Facilities 
Planner (Fitness Director) June 2015-present 
Independent Yoga Instruction- Instructor, 2003-present 
Woodford Physical Therapy- Exercise Physiologist, August 2004-October 2006  
Professional Certifications 
 
Mind Body Specialist, American Council on Exercise, December 2013 
 
Certified Group Fitness Instructor, American Council on Exercise, March 2008 
 
Certified Exercise Physiologist, American College of Sports Medicine, October 2003. 
 
Certified Yoga Instructor, YogaFit Levels 1-5, Senior, Pre-natal/Post-partum, Anatomy 
& Alignment 
 
Registered Yoga Teacher 200 hour, Yoga Alliance, May 2011  
 
Cholestech LDX Systems, February, 2008 
 
Adult, Infant, Child CPR for Healthcare Provider, American Heart Association 
 
First Aid for Healthcare Provider, American Heart Association 
 
Professional Trainings 
College Business Management Institute, Southern  Association of College and University 
Business Officers (3 year program), July 2012, July 2013, July 2014 (registered) 
Humanity Academy, University of Kentucky Human Resources Training & 
Development, November 2010 
Providing Exceptional Customer Service, University of Kentucky Human Resources 
Training & Development, July 2010  
118 
 
Health Insurance Portability and Accountability Act training, University of Kentucky 
Human Resources Training & Development 
HR Professional Standards, University of Kentucky Human Resources, 2014 
 
 
 
